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Mantle cell lymphoma patients have variable clinical courses, ranging from indolent cases not 
requiring immediate treatment to aggressive, rapidly progressing diseases. Thus, diagnostic tools 
capable to stratify patients according to their risk of relapse and death are warranted. The study 
included 83 samples from the “Fondazione Italiana Linfomi” MCL-0208 clinical trial. Through 
gene expression profiling and quantitative real-time PCR we analyzed 46 peripheral blood and 43 
formalin-fixed paraffin-embedded lymph node samples. A prediction model to classify patients was 
developed. By analyzing the transcriptome of 27 peripheral blood samples, two subgroups 
characterized by a differential expression of genes from the B-cell receptor pathway (B-cell 
receptorlow and B-cell receptorhigh) were identified. The prediction model based on the quantitative 
real-time PCR values of six representative genes (AKT3, BCL2, BTK, CD79B, PIK3CD, and SYK), 
was used to classify the 83 cases (43 B-cell receptorlow and 40 B-cell receptorhigh). The B-cell 
receptorhigh signature associated with shorter progression-free survival (P=0.0074), selected the 
mantle cell lymphoma subgroup with the shortest progression-free survival and overall survival 
(P=0.0014 and P=0.029) in combination with high (>30%) Ki-67 staining, and was independent 
predictor of short progression-free survival along with the “Mantle Cell Lymphoma International 
Prognostic Index”-c score. Moreover, the clinical impact of the 6-gene signature related to the B-
cell receptor pathway identified mantle cell lymphoma subset with shorter progression-free survival 
intervals also in an external independent mantle cell lymphoma cohort homogenously treated with 
different schedules. In conclusion, this 6-gene signature associates with a poor clinical response in 





Mantle cell lymphoma (MCL) is a distinctive B cell malignancy accounting for 5-10% of all 
lymphomas,1-3 whose molecular hallmark and initiating oncogenic event, the t(11;14)(q13;q32) 
translocation, leads to constitutive overexpression of the proto-oncogene cyclin D1 (CCND1).2,4 
 
Once considered as uniformly characterized by a poor prognosis, MCL has been demonstrated to 
have unexpectedly variable clinical courses, ranging from indolent cases not requiring immediate 
treatment to aggressive, rapidly progressing disease.2,5-10 Even among patients requiring treatment, 
prognosis is highly heterogeneous, with patients experiencing prolonged remissions and others 
rapidly relapsing even after cytarabine-containing induction regimens followed by autologous 
transplantation. Thus, diagnostic tools capable to stratify MCL patients in different risk classes are 
warranted, in order to direct treatment strategies.11 For this reason, many attempts have been made 
to identify clinical, histologic, and molecular markers that allow the stratification of patients 
according to their risk of relapse and death.12-25 
 
In addition to the clinical MCL prognostic score (MCL-International Prognostic Index, MIPI)12,14 
capable to stratify patients into risk groups with different overall survival,14 the Ki-67 proliferation 
index has been proposed as one of the most powerful and independent predictor of survival in MCL 
even in the context of prospective trials and modern therapies,5,13,26 and for these reasons integrated 
in the so-called MIPI-c score.13,26 Moreover, effective prognostic discrimination is achieved by 
post-treatment response monitoring by PET-scan and minimal residue disease. Furthermore, a 
seminal study identified a specific signature associated with proliferation as the strongest predictor 
of overall survival in a large MCL series.20 In this context, a cohort of 20 proliferation-associated 
genes constructed on the basis of gene expression analysis was demonstrated to be superior to other 
molecular markers.20 Since approaches based on microarray technology cannot be still applied for 
routine clinical purposes, a PCR-based surrogate method investigating expression of five genes has 
been proposed and applied to paraffin-embedded tissues.18 
 
Recent evidences suggest that the B-cell receptor (BCR) pathway may contribute to the 
pathogenesis of several histological types of B-cell non-Hodgkin lymphomas, including MCL.27-30 
The importance of BCR signaling pathway in B-cell malignancy pathogenesis has driven interest in 
the use of small-molecule inhibitors of BCR-associated kinases, potentially preventing the 
activation of one or more of the distal BCR signaling pathway proteins.28,31 
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In the present study, we developed a survival predictive model for younger patients with advanced 
MCL, treated in the context of the “Fondazione Italiana Linfomi” (FIL) MCL-0208 phase III 
randomized clinical trial. Notably, this model, based upon the quantitative evaluation of six genes, 
mostly from BCR pathway, as selected from a gene expression profile (GEP) of peripheral blood 
(PB) MCL cells, and applicable to formalin-fixed paraffin-embedded (FFPE) tissue specimens, 





Primary MCL cases 
The study included 83 out of 300 samples of adult patients aged<66 years with advanced stage 
MCL, enrolled in the “FIL-MCL-0208” prospective, multicenter, phase III randomized clinical trial 
(NCT02354313),32 divided as follows: i) a panel of 27 PB samples utilized for GEP upon positive 
sorting of the clonal CD5+/CD19+ MCL cells; ii) an additional panel of 19 PB samples utilized for 
quantitative real time PCR (qRT-PCR) of the identified gene signature in the purified MCL cell 
component; iii) a panel of 43 lymph nodes (LN) samples utilized for qRT-PCR of the identified 
gene signature; in this LN panel 6 samples had a matched PB sample. The clinical and histo-
pathological details of the 83 MCL cases used in this study are reported in Table 1. No significant 
differences were found between the 83 cases entering the study versus the 217 remaining cases 
enrolled in the clinical trial in term of median age, MIPI score, Ki-67 index and PFS intervals 
(Table S1 and Figure S1). No differences were observed between PB and LN MCL samples 
regarding the clinical and biological parameters (not shown). All patients were treated according to 
the FIL-MCL-0208 clinical trial as reported in Figure S2.  
MCL diagnosis was prospectively confirmed by centralized histological review according to the 
2008 WHO criteria.3,33 All patients provided informed consent in accordance with Institutional 
Review Board requirements (0016331-BZ 09/02/2010) and declaration of Helsinki and protocol 
consent included use of MRD sample leftovers for the study. 
All the procedures employed for RNA extraction, GEP and downstream analyses, qRT-PCR, 
analyses and qRT-PCR validations were done following standard protocols, as reported 
previously.34-37 Details are reported in Supplemental Information. Microarray data are available in 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers 
GSE89447. Cases used for these procedures were reported in Table S2. 
 
Validation procedures 
The 6-gene signature was tested in the MCL cohort described by Saba et al,30 enrolled in another 
clinical trial (NCT00114738), by using the sum of the array gene expression values, as reported.30 
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Gene signatures related to MCL outcome were retrieved from previous papers,30,38 and imported in 
the GeneSpring GX and tested in the present cohort with GEP data available. 
 
Statistical analysis 
Overall survival (OS) was computed from trial registration to death as a result of any cause, 
censored at the latest follow-up in patients who were still alive. Progression-free survival (PFS) was 
computed from trial registration to progression or death as a result of any cause, censored at the 
latest tumor assessment if no progression was observed. Clinical correlations, performed with the 
MedCalc v9.5 software, were made using Kaplan-Meier plots and log-rank test. The Cox 
proportional model was chosen for multivariable analysis. Clinical outcome results were updated as 
of January 2017.32 Investigators are still blinded to investigation arm as the study primary endpoint 





GEP Identifies MCL Patients with Distinct Expression of Genes Belonging to the BCR 
Pathway 
Global GEP was performed in purified MCL cells from 27 PB samples. As shown in Figure 1A, an 
unsupervised analysis performed by principal component analysis (PCA) divided the cohort in two 
groups of 14 cases and 13 cases, respectively. Consistently, a hierarchical clustering, which was run 
with all the GEP features, split MCL cases into two major groups perfectly resembling the PCA 
groups (Figure 1B). 
Supervised analysis according to the PCA classification defined a gene expression signature 
composed by 922 probes, 713 up-regulated and 209 down-regulated in group-2 versus group-1 
samples (Table S3 and Figure 1C). 
Pathway analysis revealed that “Antigen processing and presentation” and “B cell receptor 
signaling pathway” were among the top ranked pathways enriched in group-2 category (Table S4). 
Similar results were obtained by GSEA which highlighted a constitutive overexpression of genes 
related to the BCR signaling pathways in the context of group-2 patients (Figure 2A and Table S5). 
Therefore, hereafter the two PCA groups were identified as BCRlow (group-1) and BCRhigh (group-
2). 
 
A 6-Gene Signature Identifies BCRlow and BCRhigh MCL samples 
Having identified two different groups of MCL patients at diagnosis with a different expression of 
genes related to the BCR pathway, we overlapped the genes included in the gene sets related to 
BCR pathway (115 probes), and the differentially expressed genes (922 probes) to create a reduced 
signature (Figure 2B). In this way, 18 probes corresponding to 15 genes, all overexpressed in 
BCRhigh cases were identified (Figure 2B). Among these genes, a subgroup of six genes (AKT3, 
BCL2, BTK, CD79B, PIK3CD, and SYK) was selected for further validations due to their direct 
involvement in the BCR pathway and/or the existence of drugs targeting the related proteins. As 
shown in Figure 2C, a hierarchical cluster using only these six genes was able to discriminate 





Development of a qRT-PCR-Based Predictor for BCRlow and BCRhigh in MCL Samples 
By analyzing the expression levels of the selected six genes in the same 27 MCL PB samples by 
qRT-PCR approach, a strict correlation with GEP data was found (Figure S3B). Moreover, the 27 
MCL cases were randomly divided into a training set (17 cases; 8 BCRlow and 9 BCRhigh samples) 
and a validation set (10 cases; 6 BCRlow and 4 BCRhigh samples) to develop and test a decision tree 
(DT) model based qRT-PCR data capable to categorize patients in one of the two categories. As 
reported in Figure 2 D-E and Table S2, the DT model based on qRT-PCR data correctly classified 
16/17 cases belonging to the training set and 10/10 cases of the validation cohort, and allowed the 
classification of 19 additional PB samples screened with qRT-PCR (9 BCRlow and 10 BCRhigh, 
Table S2). 
 
Association between BCR Categories and Biological and Clinical Parameters 
Collectively, the 6-gene signature was re-evaluated by setting up a validated qRT-PCR approach 
(see Supplemental Information and Table S6) in PB samples from 46 MCL cases, 23 identified as 
BCRlow and 23 as BCRhigh. By correlating the BCR groups with the available biological parameters, 
no association was found between the 6-gene signature and IGHV gene status (P=0.93, Figure S4A 
and Table S2); Ki-67 expression, white blood cells, hemoglobin, lymphocytes, platelets, and 
neutrophils count (data not shown). The only significant difference was between the BCR 
classification and LDH levels; as shown in Figure S4B, BCRhigh cases showed higher level of LDH 
respect to BCRlow MCL (416.6±191.6 versus 292.2±127.4, P=0.023). 
Clinically, MCL patients classified as BCRhigh, experienced shorter PFS respect to BCRlow MCL 
cases (median PFS: 21.6 months versus not reached, P=0.0375; Figure 3).  
 
Application of the 6-Gene Signature to LN samples from MCL patients 
To evaluate the capability of the 6-gene signature to identify different subgroups also in the context 
of MCL LN cases, we tested our qRT-PCR approach in a series of 43 LN samples preserved as 
FFPE LN specimens. Thirty-five (81%) out of 43 samples were amplifiable for all six genes, and as 
reported in Table S2, using a DT model based on qRT-PCR values from FFPE, 23 cases were 
classified as BCRlow and 20 classified as BCRhigh. Notably, for 6 out of 43 LN samples, a PB 
matched sample was available, and by comparing qRT-PCR results performed on PB samples and 
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LN FFPE samples from these cases, a good concordance was overall observed, although FFPE 
samples generally amplified at higher Ct values (Figure S5). Of note, 5 out of 6 these MCL cases 
were consistently classified. The misclassified case was considered as BCRlow according to GEP 
data. Also in the context of LN samples, no correlation was found between the different biological 
parameters and BCR groups (not shown).  
By merging the MCL cases analyzed either in PB or in LN, a total of 83 cases were collected, 43 
BCRlow and 40 BCRhigh. As shown in Figure 4A, BCRhigh patients had a shorter PFS with respect to 
BCRlow patients (median PFS: 42.1 months versus not reached, P=0.0074). Being Ki-67 a well-
known prognosticator in MCL,26 we combined the BCR groups with the prognostic groups defined 
by Ki-67 score. As reported in Figure 4B, cases with high Ki-67 (≥30% of Ki-67 expressing cells) 
and classified in the BCRhigh group experienced the shortest PFS, while cases classified as BCRlow 
had similar longer PFS intervals irrespective to the high or low Ki-67 score (median PFS: 20.5 
months versus not reached for all the other combinations; P=0.0014). Consistently, multivariable 
analysis carried out by including the BCR signature and the MIPI-c categories selected the BCRhigh 
and the high risk MIPI-c category as independent predictor of PFS (Table 2). Regarding OS, while 
the BCR readout failed to identify groups with different OS intervals, possibly due to the low rate 
of events and short follow-up (Figure 4C), the combination of high Ki-67 score and a BCRhigh 6-
gene signature was able again to select the MCL subgroup with the shortest OS (46.7 versus not 
reached; P=0.029; Figure 4D). 
 
Validations of BCR Signature 
To verify whether the BCR signature maintained its prognostic impact in an independent set of 
patients, we used the gene expression data of MCL LN biopsies reported by Saba et al.30 Also in 
this different setting a high expression of the 6-gene signature, as in the context of BCRhigh cases, 
identified a MCL patients subset with inferior PFS (P=0.049; Figure S6). 
In another set of analyses, by taking advantage of our 27 MCL cases with GEP data available, we 
correlated our BCR signature with other MCL signatures with proven clinical impact.30,38 As 
reported in Figure S7A, the BCR signature reported in Saba et al,30 divided MCL cases in two 
groups exactly corresponding to our BCR definition (Figure S7B).30 Similarly, the 17 genes of the 
proliferation signature reported by Scott et al,38 split our MCL cases in 3 different groups 
resembling the 3 different groups originally defined (Figure S8A). In this context, the shortest PFS 
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and OS intervals were observed in the third group characterized by higher expression of genes 





In this study, we demonstrated that a BCR-derived signature based upon the differential expression 
of six genes correlated with shorter PFS intervals in the context of a phase III, prospective clinical 
trial (FIL-MCL-0208) for younger MCL patients receiving R-CHOP induction, followed by high-
dose cytarabine and autologous stem cell transplantation (NCT023541313).32 
Notably, the BCR-related 6-gene signature reported here was able to identify MCL subset with 
shorter PFS intervals also in the context of an external independent MCL cohort homogenously 
treated with different schedules.30 On the other hand, when the signature described by Saba et al,30 
and Scott et al,38 were applied to our MCL cases, the patients subsets with the worse prognosis 
turned out particularly enriched in BCRhigh cases, even though these signatures did not include any 
gene from our signature. Therefore, although composed by genes located up-stream the BCR 
machinery, our signature was able to identify cases with an active BCR pathway as defined by other 
signature.30 In this regard, however, experiments with primary MCL cases and/or MCL cell lines 
Combinating the BCR stimulation with the use of specific BCR inhibitors should be performed to 
investigate the contribution of the 6-gene signatures described here to the actual activation of the 
BCR pathway. 
 
Again in agreement with this line of reasoning, BCRhigh samples presented a significant up-
regulation of PAX5 (see GEP data, Table S3), a gene whose product is known to prevent plasma 
cell differentiation thus preserving the capacity to respond to antigen-induced activation and 
proliferation.39 Taken together these data corroborate recent findings of ongoing active BCR 
signaling in MCL cell in vivo,29,30 and further underline the role of antigen stimulation in the 
ontogeny of MCL as suggested by the skewed IGVH gene repertoire found in MCL cells.40 
In order to discriminate between BCRlow and BCRhigh MCL samples, we developed a DT model 
based upon the expression of the selected six genes28 This DT model was applied in an independent 
cohort of PB samples and then to a further series of FFPE LN samples, thus demonstrating that two 
MCL subsets with different expression levels of BCR-related genes could be recognized also in the 
LN compartment, mirroring the PB. Altogether, by combining data from the PB and LN 
compartments, MCL cases classified as BCRhigh, showed higher LDH levels and shorter PFS 
respect to BCRlow patients, suggesting that activation of BCR signaling drives tumor proliferation 
and determines clinical outcome of MCL patients which is in keeping with recent findings.30 
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By combining the predictive capacity of the 6-gene BCR signature with the Ki-67 index, we 
identified a particularly unfavorable category (BCRhigh, and high Ki-67) with a substantially shorter 
PFS and OS respect to the other groups. Consistently, the BCRhigh signature turned out independent 
prognosticator along with the high risk MIPI-c category for short PFS by multivariate analysis. 
There is no indication that the validity of the model may be affected by the different recruitment site 
(PB versus LN), or by different sample storage (frozen versus FFPE) because the main clinical 
parameters were equally distributed between the different series (PB/frozen versus LN/FFPE; R.B., 
unpublished observation). In this regard, an important feature of this model/assay is its applicability 
to both PB and LN FFPE samples, having therefore the chance to combine results of qRT-PCR with 
Ki-67 staining in all the cases. 
Our data underscore the increasing importance of BCR-related genes in the pathogenesis and 
development of MCL, further underlined by the clinical significance of drugs specifically targeting 
genes belonging to this pathway. In particular, therapeutic targeting of BTK,41 can be rationally 
exploited in lymphoid malignancies proved to be addicted to an antigen-dependent BCR-mediated 
active signaling. However, despite the relative high response rate to single agent ibrutinib in 
relapsed/refractory MCL, it remained unclear why some patients showed pronounced responses, 
while others received little therapeutic benefit.31,42 The BCR-related signature, here described, may 
provide molecular insights explaining the divergent responses of MCL patients to ibrutinib, 
although other causes of primary resistance might be related to gene mutations in the other 
pathways, e.g. NF-kB pathway and epigenetic modifiers, as recently reported.43,44 
In conclusion, in the present study we developed a survival model for patients with MCL composed 
by six genes (AKT3, BTK, CD79B, PIK3CD, SYK, BCL2) whose expression can be easily 
investigated by qRT-PCR and also in FFPE specimens. The signature was associated with a poor 
clinical response in the context of a high-dose chemo-immuno therapy regimen, and might be 
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Table 1. Characteristics of 83 MCL cases entering the study 
  Samples 
Number of cases 83 
Median age (range) 56 (28-65) 
Ratio male/female (%) 57/26 (68) 
Abnormal LDH (%) 45/29 (39) 
Median WBC (10-9/L) 13.7 
Typical Morphology 74 
Blastoid Morphology 5 
Median Proliferation Index (Ki-67 staining), % 20.0 (0-99) 
MIPI-c class 
Low 38 (46%) 
Low/intermediate 23 (28%) 
High/intermediate 11 (13%) 
High 6 (7%) 
na 5 (6%) 
Median Survival, months (range) 34.7 (1.4-73.4) 
Median Progression Free Survival, months (range) 31.3 (1.4-73.4) 




Table 2. Cox regression analysis on MCL cases 
  Univariable Multivariable 
Variable HR (95%CI) p value HR (95%CI) p value 
BCR signature 
    
BCR high 2.81 (1.28 to 6.19) 0.01 3.48 (1.47 to 8.25) 0.005 
     
MIPI-C 
    
Low/intermediate 1.5 (0.6 to 3.73) 0.384 
  
High/intermediate 1.41 (0.45 to 4.43) 0.557 
  
High 3.46 (1.1 to 10.91) 0.034 4.17 (1.3 to 13.34) 0.016 
Multivariable Cox regression analyses of PFS was performed by including the 6-
gene BCR categorization and the MIPI-c score as defined by Hoster et al 13. 
HR, Hazard ratio; CI, Confidence Interval; BCR, B Cell Receptor; MIPI-c, MCL 





Figure 1. Gene Expression Profile (GEP) analysis of 27 MCL samples. A) Principal Component 
Analysis (PCA) scores represented in a 3D scatter plot. One point per array/sample is shown. Black 
line indicates separation between PCA classes. B) Hierarchical clustering of 14 group1 cases and 13 
group2 cases, using 50 739 probes, is shown. C) Hierarchical clustering of 14 group1 cases and 13 
group2 cases, using the 922 differentially expressed probes, is shown. Color codes for gene 
expression values refer to mean centered log-ratio values. 
 
Figure 2. 6-gene signature and Decision Tree (DT) prediction model. A) GEP data of BCRlow 
and BCRhigh MCL samples were tested using Gene set enrichment analysis (GSEA). Reported are 
the significantly gene sets differentially expressed and related to the B-Cell Receptor (BCR) 
pathway. B) Venn diagram derived by merging the differentially expressed probes and the genes 
belonging to the BCR related gene sets. In bold genes selected as the 6-gene signature. C) 
Hierarchical clustering of 14 BCRlow cases and 13 BCRhigh cases, using the six gene values, is 
shown. Color codes for gene expression values refer to mean centered log-ratio values. D) 
Hierarchical clustering of 8 BCRlow cases and 9 BCRhigh cases belonging to the training set of DT 
prediction model, using the six gene qRT-PCR values, is shown. E) Hierarchical clustering of 6 
BCRlow cases and 4 BCRhigh cases belonging to the validation set of DT prediction model, using the 
six gene qRT-PCR values, is shown. Bar under the heat-map refers to prediction generated by the 
DT prediction model. Color codes for gene expression values refer to mean centered log-ratio 
values. 
 
Figure 3. BCRhigh MCL group is associated with a worse clinical outcome. Kaplan-Meier curves 
obtained by comparing PFS intervals of 23 BCRlow MCL cases with 23 BCRhigh MCL cases. The 
number of patients in each group is reported under relative categories; P value refers to log-rank 
test. 
 
Figure 4. BCRhigh MCL group is associated with a worse clinical outcome (overall series). A) 
Kaplan-Meier curves obtained by comparing PFS intervals of 43 BCRlow MCL cases with 40 
BCRhigh MCL cases. B) Kaplan-Meier curves obtained by comparing PFS intervals of 19 BCRlow 
and low Ki-67 MCL cases, with 20 BCRlow and high Ki-67 MCL cases, with 21 BCRhigh and Ki-67 
23 
 
low MCL cases, with 10 BCRhigh and Ki-67 high MCL cases. C) Kaplan-Meier curves obtained by 
comparing OS intervals of 43 BCRlow MCL cases with 40 BCRhigh MCL cases. D) Kaplan-Meier 
curves obtained by comparing OS intervals of 19 BCRlow and low Ki-67 MCL cases, with 20 
BCRlow and high Ki-67 MCL cases, with 21 BCRhigh and Ki-67 low MCL cases, with 10 BCRhigh 
and Ki-67 high MCL cases. The number of patients in each group is reported under relative 
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RNA extraction and GEP 
The purity of purified clonal CD5+/CD19+ MCL cells, using a cell sorting FACSAriaIII (BD 
Biosciences, Franklin Lakes, NJ), always exceeded 95%. Total RNA was extracted using the 
TRIZOL Reagent (Thermo Fisher Scientific) according to protocol. In the case of FFPE MCL 
samples, RNA extraction was performed strictly following the RecoverAll Total Nucleic Acid 
Isolation Kit for FFPE (Thermo Fisher Scientific) instructions. RNA was checked using the Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), as reported previously.1-4 
 
GEP and data mining tools 
GEP was performed with 150 ng total RNA labeled with Cyanine(Cy)-3 dye.1,2 Cy3-labeled RNA 
was hybridized to the Whole Human Genome (8x60) oligo microarray (Agilent Technologies) and 
analyzed with an Agilent Microarray Scanner (Agilent Technologies) and with the Agilent Feature 
Extraction Software 10.7.3 (Agilent Technologies), as reported previously.1-4 Microarray data are 
available in Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number 
GSE89447. 
 
Gene Expression Profiling (GEP) data mining tools 
GEP data were analyzed using the GeneSpring GX 12.7 software (Agilent Technologies, Santa 
Clara, CA); pre-processing and pre-filtering steps were carried out according to Agilent instruction. 
To identify the differentially expressed genes, t statistic was applied and P values were then 
adjusted for multiple testing with Benjamini and Hochberg's method to control the false discovery 
rate. Differentially expressed genes were identified according to an adjusted P value ≤ 0.01 and a 
fold change at least equal to 3. GEP results were visualized using the Cluster and Tree View 
programs (Eisen Laboratory, Stanford University).5 The biological functions of genes were 
investigated using Onto-Tools.3 Significant gene ontology pathways differentially expressed were 
selected for having a P value of at least 0.05, and containing at least five genes per category. Gene 
Set Enrichment Analysis (GSEA)1,2,4,6 was used to identify the putative genes sets involved in gene 
deregulation from the online database available at the GSEA Web site 
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(http://www.broadinstitute.org/gsea/). Enriched or over-represented genes sets between BCRlow and 
BCRhigh MCL samples were identified using 1 000 permutations of the phenotype labels. Venn 
diagram was constructed using genes belonging to the different gene sets related to B-Cell Receptor 
(BCR) pathway and having a significant enrichment score after conversion into Agilent probes and 
merged with probes differentially expressed with an adjusted P value ≤ 0.01 and a fold change at 
least equal to 3. 
 
Quantitative real-time PCR (qRT-PCR) 
First strand cDNA synthesis was performed by using ImProm-II Reverse Transcription System 
(Promega) following the manufacturer’s instructions, using 150 ng of RNA with 0.5 ug/reaction of 
Random primers. Expression of specific genes was evaluated with the Gene Expression assay kit 
(Integrated DNA Technologies, Coralville, IA) using 1 x FastStart Universal Probe Master Mix 
ROX (ROCHE).1,2 All qRT-PCR experiments were performed on a Bio-Rad CFX96 (Bio-Rad 
Laboratories, Hercules, CA). Thermocycling was performed as follow: 95°C for 10 min; 40 cycles 
of 95°C for 15 s, 60°C for 1 min. The relative amount of each gene was computed using the 
equation 2-∆Ct, where ∆Ct=(Ctgene – Ctβ2M). Fold-change between classes was calculated as 
reported.1,2 Amplification efficiency for each probe was calculated with a standard curve generated 
using a cDNA from a cell line. Four different 10 fold dilutions were used to construct the relative 
standard curves. For each qRT-PCR assays a R2>0.98 and a slope between -3.28 and -3.39 was 
observed. For details related to primer and probe sequences, amplicon length and efficiency see 
Table S6. 
In order to test the reproducibility for RNA isolation and qRT-PCR experiments, we isolated RNA 
material from four different samples in triplicate, and we tested the reproducibility of each qRT-
PCR assay. A minimum variation among the mean of each replicate related to a single assay was 
observed (Figure S9A). Accordingly, the relative amount of each gene, normalized as above 
described, presented minimum variation (Figure S9B). 
 
Generation of Prediction Model 
We used the Decision Tree (DT) model implemented by GeneSpringGX 12.7 (Agilent 
Technologies). Briefly, the goal of DT model is to create a model that predicts as outcome the class 
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to which the data belongs. GeneSpring implements Axis Parallel Decision Trees where decisions at 
each step are made using one single feature of the many features present. The decision points in a 
decision tree are called internal nodes. A sample gets classified by following the appropriate path 
down the decision tree. All samples which follow the same path down the tree are said to be at the 
same leaf. The tree building process continues until each leaf has purity above a certain specified 
threshold, i.e., of all samples which are associated with this leaf, at least a certain fraction comes 
from one class. Once the tree building process is done, a pruning process is used to prune off 
portions of the tree to reduce chances of over-fitting. 
Prediction models were built based on the expression profile of the 6-gene signature (AKT3, BCL-2, 
BTK, CD79b, PIK3CD, SYK) of conditions BCRlow and BCRhigh. The input data set is divided into a 
training dataset (17 samples) and a validation dataset (10 samples) as reported in Fig. 2D-E and 
Table S2. As parameter we selected pessimistic error for pruning methods, Gini functions, Global 
allowable leaf impurity percentage, and N-Fold cross validation with 10 fold and 100 repeats.  
In the case of qRT-PCR values on FFPE samples, being hierarchical cluster again able to split 
samples in two different group resembling BCRlow (low expression of the 6-gene signature) and 
BCRhigh (high expression of the 6-gene signature) categories, we decided to use 16 samples with 
low or high expression of the 6-gene signature as training dataset for the construction of DT model 
based (see Table S2 for training samples). Accordingly to this model we assigned each FFPE MCL 
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Figure S1. Cases entering the study. A) Kaplan-Meier curves obtained by comparing PFS 
intervals of 83 MCL cases entering the biological study (median PFS not reached) with 218 MCL 
cases not entering the biological study (median PFS 57.9 months). B) Kaplan-Meier curves 
obtained by comparing OS intervals of 83 MCL cases entering the biological study (median OS not 
reached) with 218 MCL cases not entering the biological study (median OS not reached). The 
number of patients included in each group is reported under relative categories; the reported P value 
refers to log-rank test. 
 
Figure S2. Flowchart describing the Fondazione Italiana Linfomi (FIL)-MCL-0208 
randomized Italian clinical trial. 
 
Figure S3. Analysis of the 6-gene signature using array and qRT-PCR values. Correlation 
between GEP and qRT-PCR. Log2 ratios of array data are plotted in comparison with log2 of 2-∆Ct 
values obtained from qRT-PCR Gene Expression Assays (Integrated DNA Technologies, 
Coralville, IA). β2M was used as housekeeping gene. The reported P and R2 values refer to 
correlation test. 
 
Figure S4. BCR and biological parameters. A) Correlation between BCR categories and IGHV 
mutational status. P values indicate χ2 test. B) Levels of lactic dehydrogenase (LDH). Box plots 
display levels of LDH in 21 BCRlow MCL cases (273.9±113.4) and 21 BCRhigh MCL cases 
(398.6±186.3). P value indicates Mann-Whitney test. 
 
Figure S5. Correlation between qRT-PCR calculated on PB and FFPE MCL samples. Graph 
lines reporting the normalized qRT-PCR values calculated on PB or LN specimens for each 
samples. Blue line refers to PB samples; red line refers to LN samples. The reported Ic values refer 
to interclass correlation coefficient. 
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Figure S6. Validation of BCR signature in an external cohort. Validation of the 6-gene BCR 
signature in an external cohort. Probabilities of PFS were evaluated in a validation cohort of 34 
MCL cases., as reported by Saba et al.7 The separation of the 34 patients into 9 BCRhigh and 25 BCRlow 
according to the sum of the expressione of the 6 genes, as obtained by GEP data, was based on 
statistical analyses computing the optimal cutoff point, i.e. the lowest P-value. The number of patients 
in each group is reported; P value refers to log-rank test. 
 
Figure S7. Validation with external signature. Hierarchical clustering of 14 BCRlow cases (blue 
bar under the horizontal dendrogram) and 13 BCRhigh cases (red bar under the horizontal 
dendrogram), using the BCR signature retrieved by Saba et al., is shown. The reported P value 
refers to log-rank test. B) Levels of BCR activation according to Saba et al. Box plots display levels 
of BCR activation in 14 BCRlow MCL cases and 13 BCRhigh MCL cases. P value indicates Mann-
Whitney test. 
 
Figure S8. Validation with external signature. A) Hierarchical clustering of 14 BCRlow cases 
(blue bar under the horizontal dendrogram) and 13 BCRhigh cases (red bar under the horizontal 
dendrogram) using the BCR signature retrieved by Scott et al., is shown. Color codes for gene 
expression values refer to mean centered log-ratio values. B) Kaplan-Meier curves obtained by 
comparing PFS intervals of 13 Group 1 MCL cases (median PFS not reached), with 7 Group 2 
MCL cases (median PFS 49.3 months), with 7 Group 3 MCL cases (median PFS 9.1 months). C) 
Kaplan-Meier curves obtained by comparing OS intervals of 13 Group 1 MCL cases (median OS 
not reached), with 7 Group 2 MCL cases (median OS not reached), with 7 Group 3 MCL cases 
(median OS 16.4 months). The number of patients included in each group is reported under relative 
categories; the reported P value refers to log-rank test. 
 
Figure S9. Reproducibility of RNA extraction and qRT-PCR methods. A) Bars reported the Ct 
value for each gene belonging to 6-gene signature. B) Bars reported the normalize value for each 
gene belonging to 6-gene signature. In all graphs data represent mean ± standard deviation of three 
replicates for each sample. 
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AKT3 BTK CD79B PIK3CD SYK BCL2
Table S1. Features of the study population
Cases entering the study Cases not entering the study p value
N. of cases 83 217
Median age, years 54.3 55.9 ns
Male 70% 81% 0.041
Stage IV 99% 92% ns
MIPI (n=83/n=217) 
Low 47% 58%
Intermediate 35% 28% ns
High 18% 14%
Ki67 >30% (n=70/n=167) 43% 52% ns
Follow-up, years 3.1 2.8 ns
2-years PFS 78% 74% ns
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101 Female LN BCRhigh BCRhigh M No 0
104 Male LN T BCRlow BCRlow nd na 0
106 Male LN BCRhigh BCRhigh UM Yes 2
401 Male LN BCRhigh BCRhigh UM No 0
402 Male LN T BCRlow BCRlow M No 0
405 Male LN T BCRhigh BCRhigh UM No 0
406 Male LN T BCRhigh BCRhigh nd No 0
413 Male LN T BCRhigh BCRhigh UM Yes 2
417 Male LN BCRlow BCRlow M Yes 0
418 Male LN BCRlow BCRlow nd No 0
420 Male LN T BCRlow BCRlow M Yes 2
509 Male LN BCRlow BCRlow UM Yes 2
514 Female LN BCRlow BCRlow UM No 2
518 Male LN BCRlow BCRlow UM No 2
521 Male LN T BCRlow BCRlow nd na 2
1002 Male LN T BCRhigh BCRhigh nd No 0
1102 Female LN BCRhigh BCRhigh UM No 0
1305 Female LN T BCRhigh BCRhigh UM Yes 0
1308 Female LN T BCRhigh BCRhigh UM No 2
1403 Male LN T BCRhigh BCRhigh nd No 2
1702 Male LN BCRlow BCRlow UM No 2
2302 Female LN BCRlow BCRlow M No 0
2402 Male LN BCRhigh BCRhigh UM No 0
2403 Male LN T BCRhigh BCRhigh nd Yes 0
2503 Male LN BCRlow BCRlow nd No 0
2902 Male LN BCRhigh BCRhigh UM No 2
3003 Female LN BCRlow BCRlow UM No 0
3006 Male LN BCRlow BCRlow UM Yes 0
3008 Female LN BCRlow BCRlow UM Yes 2
3702 Male LN BCRhigh BCRhigh UM No 0
3705 Male LN BCRlow BCRlow UM Yes 2
3708 Female LN T BCRhigh BCRhigh nd No 0
4002 Female LN BCRlow BCRlow nd Yes 2
4402 Male LN T BCRlow BCRlow nd No 0
4404 Male LN BCRhigh BCRhigh UM No 0
4702 Male LN T BCRlow BCRlow nd No 2
5101 Male LN T BCRlow BCRlow nd No na
105 Male PB BCRhigh BCRhigh UM Yes 2
205 Female PB V BCRlow BCRlow UM na na
301 Male PB T BCRhigh BCRhigh M na 0
306 Male PB BCRhigh BCRhigh UM No 0
404 Male PB T BCRlow BCRlow UM Yes 2
408 Female PB V BCRlow BCRlow UM No 0
409 Male PB V BCRlow BCRlow UM Yes 0
410 Male PB T BCRhigh BCRhigh UM No 0
412 Female PB V BCRhigh BCRhigh UM Yes 0
505 Male PB V BCRlow BCRlow UM Yes 2
506 Male PB T BCRhigh BCRhigh UM No 0
507 Male PB T BCRlow BCRlow UM Yes 0
511 Male PB BCRlow BCRlow nd No 2
513 Male PB BCRhigh BCRhigh UM Yes 0
601 Male PB T BCRhigh BCRhigh M Yes 0
604 Male PB V BCRhigh BCRhigh UM No 2
610 Male PB BCRhigh BCRhigh UM Yes 0
703 Male PB V BCRhigh BCRhigh M Yes 0
707 Male PB V BCRhigh BCRhigh UM Yes 0
802 Female PB T BCRhigh BCRhigh UM No 0
1201 Female PB V BCRlow BCRlow UM No 0
1307 Female PB BCRlow BCRlow UM No 0
1309 Male PB BCRhigh BCRhigh UM Yes na
1513 Male PB BCRlow BCRlow nd No 0
1606 Female PB BCRhigh BCRhigh M Yes na
1701 Female PB T BCRlow BCRlow UM No 2
1901 Female PB T BCRhigh BCRhigh UM No 0
2001 Male PB T BCRlow BCRlow UM Yes 0
2103 Female PB BCRlow BCRlow nd na na
2301 Male PB T BCRlow BCRlow M No 0
2310 Female PB BCRlow BCRlow M Yes 2
2602 Male PB T BCRlow BCRlow UM No 0
3304 Female PB T BCRlow BCRlow UM No 2
3401 Male PB BCRhigh BCRhigh UM Yes 2
Table S2. BCR categorization
4103 Male PB BCRhigh BCRhigh UM No 2
4301 Female PB V BCRlow BCRlow UM Yes 2
4305 Male PB BCRhigh BCRhigh UM na na
4703 Female PB BCRlow BCRlow UM No 2
5202 Male PB BCRlow BCRlow UM No 0
5206 Female PB BCRhigh BCRhigh UM na na
102 Male PB/LN T BCRlow BCRhigh BCRlow nd Yes 2
411 Male PB/LN BCRlow BCRlow BCRlow M No 0
2501 Male PB/LN T BCRhigh BCRhigh BCRhigh UM No 0
2901 Male PB/LN T BCRhigh BCRhigh BCRhigh nd na 2
3701 Female PB/LN T BCRhigh BCRhigh BCRhigh M No 0
3706 Male PB/LN BCRlow BCRlow BCRlow UM na 2
PB: Peripheral Blood; LN: Lymph Node; DT: Decision Tree model; UM: Unmutated IGHV; M: Mutated IGHV; nd: not done; na: not available; T: Training 
dataset; V: Validation dataset.










A_23_P131899 SDCBP2 Homo sapiens syndecan binding protein (syntenin) 2 (SDCBP2), transcript variant 1, mRNA [NM_080489] 3.837 down 1
A_33_P3254331 CTRC Homo sapiens chymotrypsin C (caldecrin) (CTRC), mRNA [NM_007272] 4.126 down 2
A_33_P3310070 FOXK2 Homo sapiens forkhead box K2 (FOXK2), mRNA [NM_004514] 4.114 down 3
A_33_P3651911 na
cancer susceptibility candidate 7 (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:48905] 
[ENST00000560295]
5.803 down 4
A_23_P112159 AGO2 Homo sapiens argonaute RISC catalytic component 2 (AGO2), transcript variant 1, mRNA [NM_012154] 6.121 down 5
A_23_P62642 CFAP45 Homo sapiens cilia and flagella associated protein 45 (CFAP45), mRNA [NM_012337] 6.836 down 6
A_33_P3393684 VSIG8 Homo sapiens V-set and immunoglobulin domain containing 8 (VSIG8), mRNA [NM_001013661] 7.906 down 7
A_23_P356616 ABTB2 Homo sapiens ankyrin repeat and BTB (POZ) domain containing 2 (ABTB2), mRNA [NM_145804] 3.503 down 8
A_33_P3274647 CAMK2A
Homo sapiens calcium/calmodulin-dependent protein kinase II alpha (CAMK2A), transcript variant 1, 
mRNA [NM_015981]
9.697 down 9
A_24_P781615 AOC4P Homo sapiens amine oxidase, copper containing 4, pseudogene (AOC4P), non-coding RNA [NR_002773] 4.222 down 10
A_33_P3374190 INPP5A Homo sapiens inositol polyphosphate-5-phosphatase, 40kDa (INPP5A), mRNA [NM_005539] 7.494 down 11
A_24_P26897 INPP5A Homo sapiens inositol polyphosphate-5-phosphatase, 40kDa (INPP5A), mRNA [NM_005539] 5.480 down 12
A_21_P0011503 na ens 8.473 down 13
A_33_P3287068 MTUS2-AS1 Homo sapiens MTUS2 antisense RNA 1 (MTUS2-AS1), long non-coding RNA [NR_046378] 9.289 down 14
A_23_P163639 ANKRD11 Homo sapiens ankyrin repeat domain 11 (ANKRD11), transcript variant 2, mRNA [NM_013275] 4.157 down 15
A_24_P363278 MAK Homo sapiens male germ cell-associated kinase (MAK), transcript variant 1, mRNA [NM_005906] 3.620 down 16
A_23_P154688 SLC4A11
Homo sapiens solute carrier family 4, sodium borate transporter, member 11 (SLC4A11), transcript variant 
2, mRNA [NM_032034]
3.149 down 17
A_21_P0001690 lnc-IFI44-2 LNCipedia lincRNA (lnc-IFI44-2), lincRNA [lnc-IFI44-2:1] 3.691 down 18
A_23_P204801 SLC41A2
Homo sapiens solute carrier family 41 (magnesium transporter), member 2 (SLC41A2), mRNA 
[NM_032148]
3.424 down 19
A_33_P3415596 na ens 4.343 down 20
A_33_P3225091 NUMBL Homo sapiens numb homolog (Drosophila)-like (NUMBL), transcript variant 1, mRNA [NM_004756] 6.128 down 21
A_23_P74887 SDC3 Homo sapiens syndecan 3 (SDC3), mRNA [NM_014654] 4.002 down 22
A_33_P3241884 SDC3 Homo sapiens syndecan 3 (SDC3), mRNA [NM_014654] 3.200 down 23
A_33_P3223116 HIPK2 homeodomain interacting protein kinase 2 [Source:HGNC Symbol;Acc:HGNC:14402] [ENST00000342645] 4.150 down 24
A_33_P3223121 HIPK2
Homo sapiens homeodomain interacting protein kinase 2 (HIPK2), transcript variant 2, mRNA 
[NM_001113239]
3.908 down 25
A_21_P0010208 na 0 3.171 down 26
A_23_P317756 ACSM3




Homo sapiens potassium channel tetramerization domain containing 5 pseudogene (LOC652276), non-
coding RNA [NR_015441]
3.592 down 28
A_33_P3343828 lnc-CEMP1-1 Homo sapiens cDNA FLJ44722 fis, clone BRACE3022847. [AK126677] 3.513 down 29
A_21_P0008871 FLJ42627 Homo sapiens uncharacterized LOC645644 (FLJ42627), long non-coding RNA [NR_024492] 3.690 down 30
A_33_P3354796 FLJ42627 Homo sapiens uncharacterized LOC645644 (FLJ42627), long non-coding RNA [NR_024492] 3.676 down 31
A_33_P3871347 SNED1 Homo sapiens sushi, nidogen and EGF-like domains 1 (SNED1), mRNA [NM_001080437] 3.168 down 32
A_19_P00317171 CASC8




Homo sapiens N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits (GNPTAB), mRNA 
[NM_024312]
3.258 down 34
A_33_P3640690 ZEB1 Homo sapiens zinc finger E-box binding homeobox 1 (ZEB1), transcript variant 1, mRNA [NM_001128128] 3.521 down 35
A_33_P3229702 WFIKKN1
Homo sapiens WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1 (WFIKKN1), 
mRNA [NM_053284]
6.968 down 36
A_33_P3325723 CHN1 Homo sapiens chimerin 1 (CHN1), transcript variant 1, mRNA [NM_001822] 4.822 down 37
A_33_P3432135 EPHA1-AS1 Homo sapiens EPHA1 antisense RNA 1 (EPHA1-AS1), long non-coding RNA [NR_033897] 3.884 down 38
A_33_P3265855 PRR5-ARHGAP8 Homo sapiens PRR5-ARHGAP8 readthrough (PRR5-ARHGAP8), mRNA [NM_181334] 3.359 down 39
A_33_P3250671 TCF7
Homo sapiens transcription factor 7 (T-cell specific, HMG-box) (TCF7), transcript variant 1, mRNA 
[NM_003202]
3.457 down 40
A_23_P132760 TRH Homo sapiens thyrotropin-releasing hormone (TRH), mRNA [NM_007117] 3.349 down 41
A_23_P79247 PGAP1 Homo sapiens post-GPI attachment to proteins 1 (PGAP1), mRNA [NM_024989] 3.345 down 42
A_33_P3312735 PGAP1 Homo sapiens post-GPI attachment to proteins 1 (PGAP1), mRNA [NM_024989] 3.272 down 43
A_33_P3257312 ATG2A Homo sapiens autophagy related 2A (ATG2A), mRNA [NM_015104] 3.403 down 44
A_23_P361820 ATG2A Homo sapiens autophagy related 2A (ATG2A), mRNA [NM_015104] 3.902 down 45
A_24_P4816 GABARAPL1 Homo sapiens GABA(A) receptor-associated protein like 1 (GABARAPL1), mRNA [NM_031412] 5.891 down 46
A_33_P3812669 GABARAPL1 Homo sapiens GABA(A) receptor-associated protein like 1 (GABARAPL1), mRNA [NM_031412] 4.634 down 47
A_33_P3263538 na
nuclear paraspeckle assembly transcript 1 (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:30815] 
[ENST00000501122]
3.721 down 48
A_23_P132027 SPAG4 Homo sapiens sperm associated antigen 4 (SPAG4), mRNA [NM_003116] 3.765 down 49
A_33_P3324765 CSNK1D Homo sapiens casein kinase 1, delta (CSNK1D), transcript variant 1, mRNA [NM_001893] 3.278 down 50
A_33_P3309491 PTPRU
Homo sapiens protein tyrosine phosphatase, receptor type, U (PTPRU), transcript variant 3, mRNA 
[NM_005704]
13.763 down 51
A_23_P208334 PDE4A Homo sapiens phosphodiesterase 4A, cAMP-specific (PDE4A), transcript variant 4, mRNA [NM_006202] 5.526 down 52
A_19_P00315493 LOC145474 Homo sapiens uncharacterized LOC145474 (LOC145474), long non-coding RNA [NR_027046] 3.640 down 53
A_19_P00809708 LOC145474 Homo sapiens uncharacterized LOC145474 (LOC145474), long non-coding RNA [NR_027046] 4.110 down 54
A_23_P94552 TMEM2 Homo sapiens transmembrane protein 2 (TMEM2), transcript variant 1, mRNA [NM_013390] 4.044 down 55
A_23_P142389 LSR Homo sapiens lipolysis stimulated lipoprotein receptor (LSR), transcript variant 2, mRNA [NM_205834] 4.581 down 56
A_33_P3266923 LMTK2 Homo sapiens lemur tyrosine kinase 2 (LMTK2), mRNA [NM_014916] 3.194 down 57
A_33_P3265394 WDR74 WD repeat domain 74 [Source:HGNC Symbol;Acc:HGNC:25529] [ENST00000538098] 3.738 down 58
A_21_P0004458 lnc-ARSI-1 LNCipedia lincRNA (lnc-ARSI-1), lincRNA [lnc-ARSI-1:1] 10.111 down 59
A_21_P0003035 lnc-RNF7-1 LNCipedia lincRNA (lnc-RNF7-1), lincRNA [lnc-RNF7-1:1] 3.751 down 60
A_33_P3404676 AMOT angiomotin [Source:HGNC Symbol;Acc:HGNC:17810] [ENST00000371958] 3.162 down 61
A_23_P102950 RSPH1




Homo sapiens radial spoke head 1 homolog (Chlamydomonas) (RSPH1), transcript variant 1, mRNA 
[NM_080860]
4.224 down 63
A_23_P129157 NEIL1 Homo sapiens nei endonuclease VIII-like 1 (E. coli) (NEIL1), transcript variant 2, mRNA [NM_024608] 4.258 down 64
A_21_P0006912 lnc-SMC3-1 LNCipedia lincRNA (lnc-SMC3-1), lincRNA [lnc-SMC3-1:2] 4.582 down 65
A_21_P0010580 XLOC_l2_000657 BROAD Institute lincRNA (XLOC_l2_000657), lincRNA [TCONS_l2_00000881] 3.487 down 66
A_33_P3396578 GRK5
Homo sapiens G protein-coupled receptor kinase 5, mRNA (cDNA clone IMAGE:3912936), with apparent 
retained intron. [BC018116]
4.271 down 67
A_21_P0006893 lnc-KIF20B-5 LNCipedia lincRNA (lnc-KIF20B-5), lincRNA [lnc-KIF20B-5:1] 3.154 down 68
A_33_P3250895 PSMB11
Homo sapiens proteasome (prosome, macropain) subunit, beta type, 11 (PSMB11), mRNA 
[NM_001099780]
3.377 down 69
A_21_P0007975 LINC00424 long intergenic non-protein coding RNA 424 [Source:HGNC Symbol;Acc:HGNC:42815] [ENST00000413124] 3.647 down 70
A_21_P0007497 LINC01234




Homo sapiens solute carrier family 34 (type II sodium/phosphate cotransporter), member 1 (SLC34A1), 
transcript variant 1, mRNA [NM_003052]
4.726 down 72
A_21_P0013289 LOC646588
PREDICTED: Homo sapiens uncharacterized LOC646588 (LOC646588), transcript variant X2, misc_RNA 
[XR_426148]
3.693 down 73
A_21_P0013485 XLOC_l2_014217 BROAD Institute lincRNA (XLOC_l2_014217), lincRNA [TCONS_l2_00027780] 4.303 down 74
A_33_P3303474 CYP4A11 Homo sapiens cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11), mRNA [NM_000778] 3.278 down 75
A_21_P0001471 lnc-ZBTB17-2 LNCipedia lincRNA (lnc-ZBTB17-2), lincRNA [lnc-ZBTB17-2:1] 3.221 down 76
A_21_P0007041 LINC00200 long intergenic non-protein coding RNA 200 [Source:HGNC Symbol;Acc:HGNC:30974] [ENST00000583117] 3.901 down 77
A_33_P3313283 CILP2 Homo sapiens cartilage intermediate layer protein 2 (CILP2), mRNA [NM_153221] 3.459 down 78
A_23_P412389 FGF18 Homo sapiens fibroblast growth factor 18 (FGF18), mRNA [NM_003862] 3.103 down 79
A_33_P3235262 PIP5KL1
Homo sapiens phosphatidylinositol-4-phosphate 5-kinase-like 1 (PIP5KL1), transcript variant 1, mRNA 
[NM_001135219]
3.750 down 80
A_23_P25994 LGMN Homo sapiens legumain (LGMN), transcript variant 2, mRNA [NM_001008530] 4.178 down 81
A_33_P3799936 ARHGEF10L
Homo sapiens Rho guanine nucleotide exchange factor (GEF) 10-like (ARHGEF10L), transcript variant 1, 
mRNA [NM_018125]
3.247 down 82
A_33_P3409159 SLC22A23 Homo sapiens solute carrier family 22, member 23 (SLC22A23), transcript variant 1, mRNA [NM_015482] 4.156 down 83
A_23_P396858 FZD8 Homo sapiens frizzled class receptor 8 (FZD8), mRNA [NM_031866] 3.244 down 84
A_24_P832426 B3GALTL Homo sapiens beta 1,3-galactosyltransferase-like (B3GALTL), mRNA [NM_194318] 4.267 down 85
A_33_P3413098 LOC100129550 Homo sapiens uncharacterized LOC100129550 (LOC100129550), long non-coding RNA [NR_024618] 3.394 down 86
A_23_P315571 RFTN1 Homo sapiens raftlin, lipid raft linker 1 (RFTN1), mRNA [NM_015150] 4.643 down 87
A_21_P0013889 na raftlin, lipid raft linker 1 pseudogene 1 [Source:HGNC Symbol;Acc:HGNC:23971] [ENST00000442584] 3.864 down 88
A_32_P41026 SC5D Homo sapiens sterol-C5-desaturase (SC5D), transcript variant 2, mRNA [NM_001024956] 3.155 down 89
A_23_P328206 DNMBP Homo sapiens dynamin binding protein (DNMBP), mRNA [NM_015221] 4.108 down 90
A_33_P3347035 na Homo sapiens cDNA clone IMAGE:7262526, with apparent retained intron. [BC069659] 5.251 down 91
A_33_P3390708 TMEM2 Homo sapiens transmembrane protein 2 (TMEM2), transcript variant 1, mRNA [NM_013390] 5.721 down 92
A_24_P324405 ANKRD11 Homo sapiens ankyrin repeat domain 11 (ANKRD11), transcript variant 2, mRNA [NM_013275] 3.639 down 93
A_23_P80778 DIRC2 Homo sapiens disrupted in renal carcinoma 2 (DIRC2), mRNA [NM_032839] 4.040 down 94
A_23_P166297 ABCG1
Homo sapiens ATP-binding cassette, sub-family G (WHITE), member 1 (ABCG1), transcript variant 5, mRNA 
[NM_207627]
4.285 down 95
A_21_P0005231 na 0 3.230 down 96
A_23_P203743 GAB2 Homo sapiens GRB2-associated binding protein 2 (GAB2), transcript variant 2, mRNA [NM_012296] 5.934 down 97
A_23_P154526 GRB14 Homo sapiens growth factor receptor-bound protein 14 (GRB14), transcript variant 1, mRNA [NM_004490] 3.751 down 98
A_21_P0007219 lnc-AP000769.1-1 LNCipedia lincRNA (lnc-AP000769.1-1), lincRNA [lnc-AP000769.1-1:1] 6.459 down 99
A_23_P101905 APC2 Homo sapiens adenomatosis polyposis coli 2 (APC2), mRNA [NM_005883] 5.499 down 100
A_33_P3415052 NIPAL4 Homo sapiens NIPA-like domain containing 4 (NIPAL4), transcript variant 2, mRNA [NM_001172292] 3.778 down 101
A_33_P3401753 FFAR3 Homo sapiens free fatty acid receptor 3 (FFAR3), mRNA [NM_005304] 4.966 down 102
A_33_P3298810 FFAR3 Homo sapiens free fatty acid receptor 3 (FFAR3), mRNA [NM_005304] 5.254 down 103
A_23_P127824 TNNT3 Homo sapiens troponin T type 3 (skeletal, fast) (TNNT3), transcript variant 3, mRNA [NM_001042780] 3.149 down 104
A_33_P3382229 TNNT3 Homo sapiens troponin T type 3 (skeletal, fast) (TNNT3), transcript variant 5, mRNA [NM_001297646] 5.933 down 105
A_23_P431933 CAMKK1




Homo sapiens calcium/calmodulin-dependent protein kinase kinase 1, alpha (CAMKK1), transcript variant 
3, mRNA [NM_172207]
4.297 down 107
A_23_P325631 SKI Homo sapiens v-ski avian sarcoma viral oncogene homolog (SKI), mRNA [NM_003036] 3.953 down 108
A_24_P285032 IDS Homo sapiens iduronate 2-sulfatase (IDS), transcript variant 2, mRNA [NM_006123] 4.071 down 109
A_32_P205944 RGPD5




Homo sapiens fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group) (FUT3), 
transcript variant 1, mRNA [NM_000149]
3.739 down 111
A_24_P179044 SNX9 Homo sapiens sorting nexin 9 (SNX9), mRNA [NM_016224] 8.235 down 112
A_24_P276873 ERMN ermin, ERM-like protein [Source:HGNC Symbol;Acc:HGNC:29208] [ENST00000409395] 5.065 down 113
A_33_P3250165 ERMN ermin, ERM-like protein [Source:HGNC Symbol;Acc:HGNC:29208] [ENST00000411762] 4.371 down 114
A_24_P335620 SLC7A5
Homo sapiens solute carrier family 7 (amino acid transporter light chain, L system), member 5 (SLC7A5), 
mRNA [NM_003486]
6.363 down 115
A_23_P20494 NDRG1 Homo sapiens N-myc downstream regulated 1 (NDRG1), transcript variant 2, mRNA [NM_006096] 5.034 down 116
A_23_P143016 ARID5A Homo sapiens AT rich interactive domain 5A (MRF1-like) (ARID5A), mRNA [NM_212481] 3.357 down 117
A_33_P3389342 ARID5A Homo sapiens AT rich interactive domain 5A (MRF1-like) (ARID5A), mRNA [NM_212481] 3.363 down 118
A_23_P170290 TMEM57 Homo sapiens transmembrane protein 57 (TMEM57), transcript variant 1, mRNA [NM_018202] 3.150 down 119
A_21_P0009331 TMEM92-AS1 Homo sapiens TMEM92 antisense RNA 1 (TMEM92-AS1), long non-coding RNA [NR_125805] 9.689 down 120
A_21_P0009196 TMEM92-AS1 Homo sapiens TMEM92 antisense RNA 1 (TMEM92-AS1), long non-coding RNA [NR_125805] 10.987 down 121
A_23_P58506 ELL2 Homo sapiens elongation factor, RNA polymerase II, 2 (ELL2), mRNA [NM_012081] 4.228 down 122
A_33_P3401428 TMEM38B Homo sapiens transmembrane protein 38B (TMEM38B), mRNA [NM_018112] 3.138 down 123
A_23_P139919 CHST11
Homo sapiens carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11), transcript variant 1, mRNA 
[NM_018413]
3.154 down 124
A_21_P0002056 na 0 3.469 down 125
A_33_P3294679 SMCR5
Homo sapiens Smith-Magenis syndrome chromosome region, candidate 5 (non-protein coding) (SMCR5), 
long non-coding RNA [NR_024007]
3.943 down 126
A_33_P3339531 CHADL Homo sapiens chondroadherin-like (CHADL), mRNA [NM_138481] 3.440 down 127
A_23_P5853 SAG Homo sapiens S-antigen; retina and pineal gland (arrestin) (SAG), mRNA [NM_000541] 3.534 down 128
A_23_P426305 AOC3 Homo sapiens amine oxidase, copper containing 3 (AOC3), transcript variant 1, mRNA [NM_003734] 4.095 down 129
A_33_P3279353 AZU1 Homo sapiens azurocidin 1 (AZU1), mRNA [NM_001700] 5.458 down 130
A_23_P19030 ARSI Homo sapiens arylsulfatase family, member I (ARSI), mRNA [NM_001012301] 19.301 down 131
A_33_P3239527 LOC100128517 Homo sapiens cDNA FLJ44820 fis, clone BRACE3046049. [AK126772] 5.197 down 132
A_33_P3226367 lnc-CD44-1 LNCipedia lincRNA (lnc-CD44-1), lincRNA [lnc-CD44-1:1] 8.220 down 133
A_33_P3299416 GRASP
Homo sapiens GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein (GRASP), 
transcript variant 1, mRNA [NM_181711]
3.124 down 134
A_33_P3336592 KLF13 Homo sapiens cDNA FLJ45109 fis, clone BRAWH3034097. [AK127052] 3.429 down 135
A_21_P0009442 LINC01540
Homo sapiens long intergenic non-protein coding RNA 1540 (LINC01540), transcript variant 1, long non-
coding RNA [NR_110429]
3.465 down 136
A_33_P3361896 LOC100127994 Homo sapiens cDNA FLJ45631 fis, clone CHONS2001797. [AK127538] 3.342 down 137
A_24_P286951 PLEKHS1




Homo sapiens pleckstrin homology domain containing, family S member 1 (PLEKHS1), transcript variant 1, 
mRNA [NM_182601]
3.606 down 139
A_33_P3232677 na 0 3.122 down 140
A_21_P0013391 na 0 4.124 down 141
A_23_P39550 TMEM163 Homo sapiens transmembrane protein 163 (TMEM163), mRNA [NM_030923] 5.852 down 142
A_21_P0004840 lnc-CD83-2 LNCipedia lincRNA (lnc-CD83-2), lincRNA [lnc-CD83-2:1] 4.882 down 143
A_23_P9869 CNDP1 Homo sapiens carnosine dipeptidase 1 (metallopeptidase M20 family) (CNDP1), mRNA [NM_032649] 4.912 down 144
A_33_P3281473 FAM83A-AS1 Homo sapiens FAM83A antisense RNA 1 (FAM83A-AS1), long non-coding RNA [NR_024479] 3.239 down 145
A_33_P3301351 RBM44 Homo sapiens RNA binding motif protein 44 (RBM44), mRNA [NM_001080504] 3.484 down 146
A_33_P3374087 RBM44 Homo sapiens RNA binding motif protein 44 (RBM44), mRNA [NM_001080504] 4.292 down 147
A_33_P3543133 LINC00641




Homo sapiens radial spoke head 4 homolog A (Chlamydomonas) (RSPH4A), transcript variant 1, mRNA 
[NM_001010892]
3.613 down 149
A_24_P520767 LOC149351 0 3.446 down 150
A_23_P148541 CTAG1A Homo sapiens cancer/testis antigen 1A (CTAG1A), mRNA [NM_139250] 3.802 down 151
A_24_P128442 TBX15 Homo sapiens T-box 15 (TBX15), mRNA [NM_152380] 3.910 down 152
A_21_P0001044 LINC01031
Homo sapiens long intergenic non-protein coding RNA 1031 (LINC01031), long non-coding RNA 
[NR_125789]
3.337 down 153
A_21_P0010389 na Homo sapiens cDNA FLJ46287 fis, clone TESTI4032375. [AK128164] 3.642 down 154
A_33_P3224819 SLC45A4 Homo sapiens solute carrier family 45, member 4 (SLC45A4), transcript variant 1, mRNA [NM_001286646] 7.139 down 155
A_23_P209320 PER2 Homo sapiens period circadian clock 2 (PER2), mRNA [NM_022817] 3.272 down 156
A_23_P411162 PER2 Homo sapiens period circadian clock 2 (PER2), mRNA [NM_022817] 3.187 down 157
A_24_P380311 CAMK2A
Homo sapiens calcium/calmodulin-dependent protein kinase II alpha (CAMK2A), transcript variant 1, 
mRNA [NM_015981]
7.602 down 158
A_23_P54996 TEX14 Homo sapiens testis expressed 14 (TEX14), transcript variant 1, mRNA [NM_198393] 15.998 down 159
A_23_P401106 PDE2A Homo sapiens phosphodiesterase 2A, cGMP-stimulated (PDE2A), transcript variant 1, mRNA [NM_002599] 9.232 down 160
A_24_P20200 PLEKHB2
Homo sapiens pleckstrin homology domain containing, family B (evectins) member 2 (PLEKHB2), transcript 
variant 8, mRNA [NM_001267066]
3.255 down 161
A_23_P21560 FAM49A Homo sapiens family with sequence similarity 49, member A (FAM49A), mRNA [NM_030797] 4.068 down 162
A_33_P3236392 PVRL4 Homo sapiens poliovirus receptor-related 4 (PVRL4), mRNA [NM_030916] 3.696 down 163
A_24_P149713 ZBTB43




Homo sapiens glucose-fructose oxidoreductase domain containing 1 (GFOD1), transcript variant 1, mRNA 
[NM_018988]
3.152 down 165
A_33_P3418000 RELL1 Homo sapiens RELT-like 1 (RELL1), transcript variant 2, mRNA [NM_001085399] 4.505 down 166
A_24_P322474 PDE4A Homo sapiens phosphodiesterase 4A, cAMP-specific (PDE4A), transcript variant 4, mRNA [NM_006202] 7.198 down 167
A_23_P5903 SLCO4A1
Homo sapiens solute carrier organic anion transporter family, member 4A1 (SLCO4A1), mRNA 
[NM_016354]
7.906 down 168
A_32_P5251 RARA Homo sapiens retinoic acid receptor, alpha (RARA), transcript variant 2, mRNA [NM_001024809] 3.576 down 169
A_23_P128375 FAM222A Homo sapiens family with sequence similarity 222, member A (FAM222A), mRNA [NM_032829] 4.295 down 170
A_33_P3294801 na Homo sapiens cDNA FLJ40672 fis, clone THYMU2021509. [AK097991] 3.654 down 171
A_33_P3245126 na 0 3.351 down 172
A_23_P301304 FGFR1 Homo sapiens fibroblast growth factor receptor 1 (FGFR1), transcript variant 1, mRNA [NM_023110] 4.341 down 173
A_23_P372923 FGFR1 Homo sapiens fibroblast growth factor receptor 1 (FGFR1), transcript variant 13, mRNA [NM_001174066] 3.133 down 174
A_24_P82155 ANKDD1A
ankyrin repeat and death domain containing 1A [Source:HGNC Symbol;Acc:HGNC:28002] 
[ENST00000620154]
3.180 down 175
A_23_P210763 JAG1 Homo sapiens jagged 1 (JAG1), mRNA [NM_000214] 4.692 down 176
A_23_P76823 ADSSL1 Homo sapiens adenylosuccinate synthase like 1 (ADSSL1), transcript variant 1, mRNA [NM_199165] 3.315 down 177
A_24_P253003 WNT11 Homo sapiens wingless-type MMTV integration site family, member 11 (WNT11), mRNA [NM_004626] 3.374 down 178
A_33_P3813128 SEMA3F
Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F 
(SEMA3F), mRNA [NM_004186]
3.736 down 179
A_24_P389916 LRRC32 Homo sapiens leucine rich repeat containing 32 (LRRC32), transcript variant 1, mRNA [NM_005512] 6.504 down 180
A_33_P3351249 CXCL16 Homo sapiens chemokine (C-X-C motif) ligand 16 (CXCL16), transcript variant 2, mRNA [NM_001100812] 3.928 down 181
A_33_P3623118 lnc-MGAT1-1 Homo sapiens cDNA FLJ30091 fis, clone BNGH41000017. [AK054653] 3.436 down 182
A_23_P37484 CHSY1 Homo sapiens chondroitin sulfate synthase 1 (CHSY1), mRNA [NM_014918] 3.122 down 183
A_23_P218626 NEU4 Homo sapiens sialidase 4 (NEU4), transcript variant 1, mRNA [NM_080741] 6.189 down 184
A_23_P348121 FOSL2 Homo sapiens FOS-like antigen 2 (FOSL2), mRNA [NM_005253] 7.252 down 185
A_23_P139786 OASL Homo sapiens 2'-5'-oligoadenylate synthetase-like (OASL), transcript variant 1, mRNA [NM_003733] 4.360 down 186
A_23_P10559 AATK Homo sapiens apoptosis-associated tyrosine kinase (AATK), transcript variant 1, mRNA [NM_001080395] 7.568 down 187
A_24_P96961 SPSB1 Homo sapiens splA/ryanodine receptor domain and SOCS box containing 1 (SPSB1), mRNA [NM_025106] 5.773 down 188
A_23_P134935 DUSP4 Homo sapiens dual specificity phosphatase 4 (DUSP4), transcript variant 1, mRNA [NM_001394] 4.493 down 189
A_23_P85922 BMP8A Homo sapiens bone morphogenetic protein 8a (BMP8A), mRNA [NM_181809] 11.433 down 190
A_23_P34835 LMNA Homo sapiens lamin A/C (LMNA), transcript variant 2, mRNA [NM_005572] 6.395 down 191
A_33_P3408762 LMNA Homo sapiens lamin A/C (LMNA), transcript variant 6, mRNA [NM_001282625] 7.222 down 192
A_23_P106024 JAG2 Homo sapiens jagged 2 (JAG2), transcript variant 1, mRNA [NM_002226] 4.044 down 193
A_33_P3312676 na myelin transcription factor 1  [Source:RefSeq peptide;Acc:NP_004526] [ENST00000621996] 8.594 down 194
A_33_P3233906 RAMP1 Homo sapiens receptor (G protein-coupled) activity modifying protein 1 (RAMP1), mRNA [NM_005855] 13.457 down 195
A_23_P50946 RAMP1 Homo sapiens receptor (G protein-coupled) activity modifying protein 1 (RAMP1), mRNA [NM_005855] 10.041 down 196
A_24_P51909 CPLX1 Homo sapiens complexin 1 (CPLX1), mRNA [NM_006651] 4.868 down 197
A_21_P0006238 lnc-RXRA-1 LNCipedia lincRNA (lnc-RXRA-1), lincRNA [lnc-RXRA-1:1] 3.894 down 198
A_33_P3417150 P2RY1 Homo sapiens purinergic receptor P2Y, G-protein coupled, 1 (P2RY1), mRNA [NM_002563] 3.417 down 199
A_33_P3238626 na Homo sapiens cDNA FLJ41497 fis, clone BRTHA2006075. [AK123491] 3.102 down 200
A_32_P175301 DENND3 Homo sapiens DENN/MADD domain containing 3 (DENND3), mRNA [NM_014957] 5.813 down 201
A_33_P3783812 C8orf60 Homo sapiens cDNA FLJ12193 fis, clone MAMMA1000856. [AK022255] 5.868 down 202
A_33_P3321130 DENND3 DENN/MADD domain containing 3 [Source:HGNC Symbol;Acc:HGNC:29134] [ENST00000520482] 5.856 down 203
A_23_P93938 NACAD Homo sapiens NAC alpha domain containing (NACAD), mRNA [NM_001146334] 3.194 down 204
A_21_P0010687 XLOC_l2_000018 BROAD Institute lincRNA (XLOC_l2_000018), lincRNA [TCONS_l2_00001952] 4.453 down 205
A_21_P0010689 XLOC_l2_000018 BROAD Institute lincRNA (XLOC_l2_000018), lincRNA [TCONS_l2_00001954] 5.387 down 206
A_24_P291826 SYTL3 Homo sapiens synaptotagmin-like 3 (SYTL3), transcript variant 3, mRNA [NM_001009991] 3.755 down 207
A_23_P316974 SYNJ2 Homo sapiens synaptojanin 2 (SYNJ2), transcript variant 1, mRNA [NM_003898] 3.776 down 208
A_21_P0009211 na ys84c11.r1 Soares retina N2b4HR Homo sapiens cDNA clone IMAGE:221492 5', mRNA sequence [H92146] 3.300 down 209
A_23_P373724 PPFIBP1




Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 22 (NUDT22), transcript variant 
1, mRNA [NM_032344]
4.008 up 211
A_23_P103486 CYP2J2 Homo sapiens cytochrome P450, family 2, subfamily J, polypeptide 2 (CYP2J2), mRNA [NM_000775] 5.107 up 212
A_33_P3259183 FAM78B Homo sapiens family with sequence similarity 78, member B (FAM78B), mRNA [NM_001017961] 3.448 up 213
A_33_P3346771 AK9 adenylate kinase 9 [Source:HGNC Symbol;Acc:HGNC:33814] [ENST00000466992] 5.040 up 214
A_24_P73075 TTC12 Homo sapiens tetratricopeptide repeat domain 12 (TTC12), mRNA [NM_017868] 3.842 up 215
A_23_P145541 FIG4 Homo sapiens FIG4 phosphoinositide 5-phosphatase (FIG4), mRNA [NM_014845] 4.578 up 216
A_23_P149259 TMEM79 Homo sapiens transmembrane protein 79 (TMEM79), transcript variant 1, mRNA [NM_032323] 3.729 up 217
A_33_P3320272 TMEM79 Homo sapiens transmembrane protein 79 (TMEM79), transcript variant 1, mRNA [NM_032323] 4.782 up 218
A_33_P3256113 GUSBP1
Homo sapiens glucuronidase, beta pseudogene 1 (GUSBP1), transcript variant 1, non-coding RNA 
[NR_027026]
3.781 up 219
A_33_P3220919 ADRBK2 Homo sapiens adrenergic, beta, receptor kinase 2 (ADRBK2), mRNA [NM_005160] 4.308 up 220
A_33_P3356361 SRP14-AS1
Homo sapiens SRP14 antisense RNA1 (head to head) (SRP14-AS1), transcript variant 1, long non-coding 
RNA [NR_040059]
6.041 up 221
A_33_P3386117 RER1 Homo sapiens retention in endoplasmic reticulum sorting receptor 1 (RER1), mRNA [NM_007033] 3.523 up 222
A_32_P29118 SEMA3D




Homo sapiens structural maintenance of chromosomes 6 (SMC6), transcript variant 2, mRNA 
[NM_024624]
3.788 up 224
A_21_P0001216 lnc-C1orf186-1 EST643 human nasopharynx Homo sapiens cDNA, mRNA sequence [CD684123] 6.965 up 225
A_33_P3334443 FAM69A




Homo sapiens family with sequence similarity 65, member B (FAM65B), transcript variant 1, mRNA 
[NM_014722]
3.360 up 227
A_33_P3303146 ATG4C Homo sapiens autophagy related 4C, cysteine peptidase (ATG4C), transcript variant 1, mRNA [NM_032852] 4.357 up 228
A_33_P3358923 BTLA Homo sapiens B and T lymphocyte associated (BTLA), transcript variant 1, mRNA [NM_181780] 4.615 up 229
A_33_P3412900 CBLN3 Homo sapiens cerebellin 3 precursor (CBLN3), mRNA [NM_001039771] 3.680 up 230
A_32_P180315 CCDC180 Homo sapiens coiled-coil domain containing 180 (CCDC180), mRNA [NM_020893] 4.490 up 231
A_33_P3302563 LOC100129408 Homo sapiens cDNA FLJ46023 fis, clone SPLEN2021991. [AK127916] 3.910 up 232
A_21_P0000185 LOC100505549 Homo sapiens uncharacterized LOC100505549 (LOC100505549), mRNA [NM_001242804] 3.299 up 233
A_21_P0001575 lnc-NOTCH2-2 LNCipedia lincRNA (lnc-NOTCH2-2), lincRNA [lnc-NOTCH2-2:1] 5.100 up 234
A_24_P289178 C16orf74 Homo sapiens chromosome 16 open reading frame 74 (C16orf74), mRNA [NM_206967] 3.963 up 235
A_23_P50775 LRFN3




major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC Symbol;Acc:HGNC:4943] 
[ENST00000552745]
5.537 up 237
A_23_P352266 BCL2 Homo sapiens B-cell CLL/lymphoma 2 (BCL2), transcript variant alpha, mRNA [NM_000633] 3.304 up 238
A_32_P92505 LCLAT1 Homo sapiens lysocardiolipin acyltransferase 1 (LCLAT1), transcript variant 1, mRNA [NM_182551] 3.400 up 239
A_23_P391228 MANEAL Homo sapiens mannosidase, endo-alpha-like (MANEAL), transcript variant 1, mRNA [NM_001031740] 3.224 up 240
A_33_P3413483 SORD sorbitol dehydrogenase [Source:HGNC Symbol;Acc:HGNC:11184] [ENST00000267814] 3.253 up 241
A_24_P481824 DPY19L4 Homo sapiens dpy-19-like 4 (C. elegans) (DPY19L4), mRNA [NM_181787] 3.205 up 242
A_23_P340188 FAM122C Homo sapiens family with sequence similarity 122C (FAM122C), transcript variant 2, mRNA [NM_138819] 3.865 up 243
A_33_P3315425 METTL4 Homo sapiens methyltransferase like 4 (METTL4), mRNA [NM_022840] 3.511 up 244
A_23_P28733 RBL1 Homo sapiens retinoblastoma-like 1 (RBL1), transcript variant 1, mRNA [NM_002895] 3.191 up 245
A_32_P85813 RAP1GDS1




Homo sapiens tRNA methyltransferase 1 homolog (S. cerevisiae)-like (TRMT1L), transcript variant 1, mRNA 
[NM_030934]
4.070 up 247
A_24_P145047 ZNF609 Homo sapiens zinc finger protein 609 (ZNF609), mRNA [NM_015042] 3.570 up 248
A_23_P130856 CEP89 Homo sapiens centrosomal protein 89kDa (CEP89), mRNA [NM_032816] 3.554 up 249
A_23_P80902 KIF15 Homo sapiens kinesin family member 15 (KIF15), mRNA [NM_020242] 5.393 up 250
A_23_P19816 RNF32 Homo sapiens ring finger protein 32 (RNF32), transcript variant 3, mRNA [NM_030936] 3.735 up 251
A_23_P127915 STK33 Homo sapiens serine/threonine kinase 33 (STK33), transcript variant 1, mRNA [NM_030906] 8.482 up 252
A_23_P157527 LRRCC1 Homo sapiens leucine rich repeat and coiled-coil centrosomal protein 1 (LRRCC1), mRNA [NM_033402] 5.072 up 253
A_24_P110983 AKT3
Homo sapiens v-akt murine thymoma viral oncogene homolog 3 (AKT3), transcript variant 1, mRNA 
[NM_005465]
3.105 up 254
A_24_P88801 NPHP1 Homo sapiens nephronophthisis 1 (juvenile) (NPHP1), transcript variant 1, mRNA [NM_000272] 3.502 up 255
A_33_P3260125 LDLRAD2
Homo sapiens low density lipoprotein receptor class A domain containing 2 (LDLRAD2), mRNA 
[NM_001013693]
4.256 up 256
A_21_P0005196 LOC101927902 PREDICTED: Homo sapiens uncharacterized LOC101927902 (LOC101927902), ncRNA [XR_242326] 3.777 up 257
A_21_P0010465 lnc-APOBEC3F-1 LNCipedia lincRNA (lnc-APOBEC3F-1), lincRNA [lnc-APOBEC3F-1:1] 3.867 up 258
A_23_P321160 ZNF594 Homo sapiens zinc finger protein 594 (ZNF594), mRNA [NM_032530] 3.236 up 259
A_33_P3327956 ZNF605 Homo sapiens zinc finger protein 605 (ZNF605), transcript variant 1, mRNA [NM_183238] 3.507 up 260
A_21_P0008768 LOC101929641 PREDICTED: Homo sapiens uncharacterized LOC101929641 (LOC101929641), ncRNA [XR_243223] 4.158 up 261
A_23_P201731 TRAF5 Homo sapiens TNF receptor-associated factor 5 (TRAF5), transcript variant 1, mRNA [NM_004619] 6.152 up 262
A_24_P710730 SMA4 Homo sapiens glucuronidase, beta pseudogene (SMA4), transcript variant 2, non-coding RNA [NR_024054] 3.371 up 263
A_23_P304511 ZNF397 Homo sapiens zinc finger protein 397 (ZNF397), transcript variant 2, mRNA [NM_032347] 3.951 up 264
A_23_P434430 ZNF439 Homo sapiens zinc finger protein 439 (ZNF439), mRNA [NM_152262] 5.647 up 265
A_23_P22672 ALG13
Homo sapiens ALG13, UDP-N-acetylglucosaminyltransferase subunit (ALG13), transcript variant 7, mRNA 
[NM_001257231]
3.239 up 266
A_33_P3323218 CARF Homo sapiens calcium responsive transcription factor (CARF), transcript variant 2, mRNA [NM_024744] 3.553 up 267
A_24_P363087 C5orf45 Homo sapiens chromosome 5 open reading frame 45 (C5orf45), transcript variant 1, mRNA [NM_016175] 3.156 up 268
A_24_P168398 ZNF177 Homo sapiens zinc finger protein 177 (ZNF177), transcript variant 3, mRNA [NM_003451] 8.146 up 269
A_23_P416751 ZNF610 Homo sapiens zinc finger protein 610 (ZNF610), transcript variant 3, mRNA [NM_173530] 4.020 up 270
A_23_P250245 CD72 Homo sapiens CD72 molecule (CD72), mRNA [NM_001782] 4.453 up 271
A_23_P356139 FAM178A








PREDICTED: Homo sapiens uncharacterized LOC100507616 (LOC100507616), transcript variant X1, ncRNA 
[XR_110328]
5.104 up 274
A_32_P356316 HLA-DOA Homo sapiens major histocompatibility complex, class II, DO alpha (HLA-DOA), mRNA [NM_002119] 3.902 up 275
A_23_P251705 ARHGEF9
Homo sapiens Cdc42 guanine nucleotide exchange factor (GEF) 9 (ARHGEF9), transcript variant 1, mRNA 
[NM_015185]
3.230 up 276
A_24_P344961 AMOT Homo sapiens angiomotin (AMOT), transcript variant 2, mRNA [NM_133265] 4.503 up 277
A_33_P3311917 na Q6JHZ7_HUMAN (Q6JHZ7) HCV-NS5ATP5 binding protein 1, partial (29%) [THC2537043] 3.571 up 278
A_23_P110288 GSTCD
Homo sapiens glutathione S-transferase, C-terminal domain containing (GSTCD), transcript variant 2, 
mRNA [NM_024751]
3.857 up 279
A_23_P501435 CSRP2BP Homo sapiens CSRP2 binding protein (CSRP2BP), transcript variant 1, mRNA [NM_020536] 3.620 up 280
A_32_P396186 TRIM66 Homo sapiens tripartite motif containing 66 (TRIM66), mRNA [NM_014818] 3.644 up 281
A_23_P418431 C6orf164 Homo sapiens chromosome 6 open reading frame 164 (C6orf164), long non-coding RNA [NR_026784] 3.488 up 282
A_24_P807031 ATP6AP1L
Homo sapiens ATPase, H+ transporting, lysosomal accessory protein 1-like (ATP6AP1L), mRNA 
[NM_001017971]
4.119 up 283
A_23_P52082 INTS7 Homo sapiens integrator complex subunit 7 (INTS7), transcript variant 1, mRNA [NM_015434] 4.605 up 284
A_33_P3321657 HSPG2 Homo sapiens heparan sulfate proteoglycan 2 (HSPG2), transcript variant 1, mRNA [NM_001291860] 3.109 up 285
A_23_P50786 CLIP3




Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 6 (NUDT6), transcript variant 2, 
mRNA [NM_198041]
6.013 up 287
A_33_P3241786 ADD2 Homo sapiens adducin 2 (beta) (ADD2), transcript variant 2, mRNA [NM_017482] 5.772 up 288
A_33_P3241782 ADD2 Homo sapiens adducin 2 (beta) (ADD2), transcript variant 1, mRNA [NM_001617] 4.248 up 289
A_23_P159907 MAGED4B Homo sapiens melanoma antigen family D, 4B (MAGED4B), transcript variant 1, mRNA [NM_030801] 3.960 up 290
A_19_P00810465 KCNA6
Homo sapiens potassium channel, voltage gated shaker related subfamily A, member 6 (KCNA6), mRNA 
[NM_002235]
3.199 up 291
A_23_P111635 STYXL1 Homo sapiens serine/threonine/tyrosine interacting-like 1 (STYXL1), mRNA [NM_016086] 3.630 up 292
A_24_P185604 NDRG3 Homo sapiens NDRG family member 3 (NDRG3), transcript variant 1, mRNA [NM_032013] 3.974 up 293
A_32_P154223 LINC01431




Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, beta (PIP5K1B), transcript variant 2, 
mRNA [NM_003558]
8.084 up 295
A_32_P211045 DHFR Homo sapiens dihydrofolate reductase (DHFR), transcript variant 1, mRNA [NM_000791] 6.917 up 296
A_23_P1676 TMEM218 Homo sapiens transmembrane protein 218 (TMEM218), transcript variant 1, mRNA [NM_001258243] 9.116 up 297
A_23_P217114 ALAD Homo sapiens aminolevulinate dehydratase (ALAD), mRNA [NM_000031] 3.427 up 298
A_33_P3300092 NDST1
Homo sapiens N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 (NDST1), transcript variant 1, 
mRNA [NM_001543]
4.819 up 299
A_23_P401084 ZNF575 Homo sapiens zinc finger protein 575 (ZNF575), mRNA [NM_174945] 5.194 up 300
A_23_P146637 SIGMAR1




Homo sapiens aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) (AKR7A2), mRNA 
[NM_003689]
4.752 up 302
A_23_P5731 FAHD2A Homo sapiens fumarylacetoacetate hydrolase domain containing 2A (FAHD2A), mRNA [NM_016044] 4.102 up 303
A_23_P151075 ARHGDIB Homo sapiens Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB), mRNA [NM_001175] 3.158 up 304
A_33_P3329467 STYXL1 Homo sapiens serine/threonine/tyrosine interacting-like 1 (STYXL1), mRNA [NM_016086] 4.149 up 305
A_23_P258093 AGPAT1
Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 1 (AGPAT1), transcript variant 1, mRNA 
[NM_006411]
3.165 up 306
A_23_P124927 RGS14 Homo sapiens regulator of G-protein signaling 14 (RGS14), mRNA [NM_006480] 4.359 up 307
A_23_P42746 NCF1 Homo sapiens neutrophil cytosolic factor 1 (NCF1), mRNA [NM_000265] 3.257 up 308
A_23_P91140 PECR Homo sapiens peroxisomal trans-2-enoyl-CoA reductase (PECR), mRNA [NM_018441] 6.125 up 309
A_33_P3337019 LOC728975 PREDICTED: Homo sapiens uncharacterized LOC728975 (LOC728975), misc_RNA [XR_247237] 4.550 up 310
A_23_P71855 C5 Homo sapiens complement component 5 (C5), mRNA [NM_001735] 3.238 up 311
A_23_P61487 LRRC20 Homo sapiens leucine rich repeat containing 20 (LRRC20), transcript variant 3, mRNA [NM_018205] 7.468 up 312
A_24_P168416 PRDX2 Homo sapiens peroxiredoxin 2 (PRDX2), mRNA [NM_005809] 3.833 up 313
A_23_P502654 SHMT1
Homo sapiens serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1, mRNA 
[NM_004169]
4.491 up 314
A_33_P3632937 LOC100131262 PREDICTED: Homo sapiens uncharacterized LOC100131262 (LOC100131262), misc_RNA [XR_132952] 3.665 up 315
A_33_P3337931 na 0 6.831 up 316
A_33_P3843415 WDR11-AS1 Homo sapiens WDR11 antisense RNA 1 (WDR11-AS1), long non-coding RNA [NR_033850] 4.817 up 317
A_32_P216548 LDLRAP1 Homo sapiens low density lipoprotein receptor adaptor protein 1 (LDLRAP1), mRNA [NM_015627] 3.328 up 318
A_23_P258221 ABCC5
Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 5 (ABCC5), transcript variant 1, 
mRNA [NM_005688]
5.243 up 319
A_33_P3317948 TP73-AS1 Homo sapiens TP73 antisense RNA 1 (TP73-AS1), transcript variant 1, long non-coding RNA [NR_033711] 4.382 up 320
A_23_P76529 ITGB7 Homo sapiens integrin, beta 7 (ITGB7), transcript variant 1, mRNA [NM_000889] 3.579 up 321
A_19_P00320723 SRP14-AS1




Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 5 (ABCC5), transcript variant 2, 
mRNA [NM_001023587]
10.762 up 323
A_23_P170978 ZNF692 Homo sapiens zinc finger protein 692 (ZNF692), transcript variant 2, mRNA [NM_017865] 4.191 up 324
A_23_P397543 LINC00174
Homo sapiens long intergenic non-protein coding RNA 174 (LINC00174), long non-coding RNA 
[NR_026873]
5.221 up 325
A_33_P3212172 SNX22 Homo sapiens sorting nexin 22 (SNX22), transcript variant 1, mRNA [NM_024798] 12.078 up 326
A_32_P95914 MMS22L Homo sapiens MMS22-like, DNA repair protein (MMS22L), mRNA [NM_198468] 6.498 up 327
A_33_P3305482 EIF2B3
Homo sapiens eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa (EIF2B3), transcript 
variant 1, mRNA [NM_020365]
5.174 up 328
A_23_P92543 SCFD2 Homo sapiens sec1 family domain containing 2 (SCFD2), mRNA [NM_152540] 3.300 up 329
A_23_P2223 MYL6B
Homo sapiens myosin, light chain 6B, alkali, smooth muscle and non-muscle (MYL6B), transcript variant 2, 
mRNA [NM_002475]
3.432 up 330
A_33_P3405334 GM2A Homo sapiens GM2 ganglioside activator (GM2A), transcript variant 1, mRNA [NM_000405] 5.418 up 331
A_23_P29836 TMEM42 transmembrane protein 42 [Source:HGNC Symbol;Acc:HGNC:28444] [ENST00000477126] 3.771 up 332
A_23_P160992 FMO4 Homo sapiens flavin containing monooxygenase 4 (FMO4), mRNA [NM_002022] 7.359 up 333
A_33_P3336422 ZBED5-AS1 Homo sapiens ZBED5 antisense RNA 1 (ZBED5-AS1), long non-coding RNA [NR_034137] 5.761 up 334
A_33_P3415211 MPV17 Homo sapiens MpV17 mitochondrial inner membrane protein (MPV17), mRNA [NM_002437] 3.322 up 335
A_33_P3357087 MPV17 Homo sapiens MpV17 mitochondrial inner membrane protein (MPV17), mRNA [NM_002437] 3.548 up 336
A_33_P3388312 SKAP2 src kinase associated phosphoprotein 2 [Source:HGNC Symbol;Acc:HGNC:15687] [ENST00000345317] 6.037 up 337
A_24_P89843 CYHR1 Homo sapiens cysteine/histidine-rich 1 (CYHR1), transcript variant 2, mRNA [NM_032687] 4.398 up 338
A_23_P1775 DPAGT1
Homo sapiens dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 
(GlcNAc-1-P transferase) (DPAGT1), mRNA [NM_001382]
4.625 up 339
A_23_P105409 MAP3K12
Homo sapiens mitogen-activated protein kinase kinase kinase 12 (MAP3K12), transcript variant 2, mRNA 
[NM_006301]
3.467 up 340
A_33_P3252794 GLI4 Homo sapiens GLI family zinc finger 4 (GLI4), mRNA [NM_138465] 3.314 up 341
A_23_P64828 OAS1
Homo sapiens 2'-5'-oligoadenylate synthetase 1, 40/46kDa (OAS1), transcript variant 2, mRNA 
[NM_002534]
6.161 up 342
A_23_P148807 CDC7 Homo sapiens cell division cycle 7 (CDC7), transcript variant 1, mRNA [NM_003503] 4.570 up 343
A_21_P0011476 CHEK2 Homo sapiens checkpoint kinase 2 (CHEK2), transcript variant 3, mRNA [NM_001005735] 5.260 up 344
A_23_P117494 MTHFD1
Homo sapiens methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase (MTHFD1), mRNA 
[NM_005956]
3.607 up 345
A_21_P0008517 LOC100506476 Homo sapiens uncharacterized LOC100506476 (LOC100506476), long non-coding RNA [NR_109995] 4.436 up 346
A_21_P0014231 lnc-WDR34-1 LNCipedia lincRNA (lnc-WDR34-1), lincRNA [lnc-WDR34-1:1] 3.372 up 347
A_24_P405205 ATP2B4
Homo sapiens ATPase, Ca++ transporting, plasma membrane 4 (ATP2B4), transcript variant 1, mRNA 
[NM_001001396]
3.631 up 348
A_23_P64898 KLRG1 Homo sapiens killer cell lectin-like receptor subfamily G, member 1 (KLRG1), mRNA [NM_005810] 4.193 up 349
A_21_P0014077 LOC100505666




Homo sapiens phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP), transcript 
variant 1, mRNA [NM_022126]
3.251 up 351
A_23_P24616 SIAE Homo sapiens sialic acid acetylesterase (SIAE), transcript variant 1, mRNA [NM_170601] 3.459 up 352
A_24_P212539 GALM Homo sapiens galactose mutarotase (aldose 1-epimerase) (GALM), mRNA [NM_138801] 3.121 up 353
A_33_P3273436 GALM Homo sapiens galactose mutarotase (aldose 1-epimerase) (GALM), mRNA [NM_138801] 3.194 up 354
A_23_P210015 PTPN18
Homo sapiens protein tyrosine phosphatase, non-receptor type 18 (brain-derived) (PTPN18), transcript 
variant 1, mRNA [NM_014369]
3.454 up 355
A_24_P306720 FOXN3-AS1 Homo sapiens FOXN3 antisense RNA 1 (FOXN3-AS1), long non-coding RNA [NR_036500] 3.502 up 356
A_24_P139943 HS1BP3 Homo sapiens HCLS1 binding protein 3 (HS1BP3), mRNA [NM_022460] 3.167 up 357
A_23_P130515 CEACAM3
Homo sapiens carcinoembryonic antigen-related cell adhesion molecule 3 (CEACAM3), transcript variant 1, 
mRNA [NM_001815]
3.845 up 358
A_23_P148473 IL2RG Homo sapiens interleukin 2 receptor, gamma (IL2RG), mRNA [NM_000206] 3.179 up 359
A_33_P3396607 UGDH Homo sapiens UDP-glucose 6-dehydrogenase (UGDH), transcript variant 1, mRNA [NM_003359] 5.443 up 360
A_33_P3327822 SH3BGR
Homo sapiens SH3 domain binding glutamate-rich protein (SH3BGR), transcript variant 1, mRNA 
[NM_007341]
3.274 up 361
A_21_P0006453 lnc-ZMYM3-1 LNCipedia lincRNA (lnc-ZMYM3-1), lincRNA [lnc-ZMYM3-1:1] 4.017 up 362
A_23_P139396 C11orf73
Homo sapiens chromosome 11 open reading frame 73 (C11orf73), transcript variant 1, mRNA 
[NM_016401]
3.742 up 363
A_23_P134714 HRSP12 Homo sapiens heat-responsive protein 12 (HRSP12), mRNA [NM_005836] 5.662 up 364
A_33_P3232544 na 0 3.270 up 365
A_23_P256413 CMTM7












Homo sapiens membrane-spanning 4-domains, subfamily A, member 14 (MS4A14), transcript variant 1, 
mRNA [NM_032597]
5.130 up 369
A_23_P322756 TET1 Homo sapiens tet methylcytosine dioxygenase 1 (TET1), mRNA [NM_030625] 3.387 up 370
A_33_P3308332 PLEKHB1
Homo sapiens pleckstrin homology domain containing, family B (evectins) member 1 (PLEKHB1), transcript 
variant 1, mRNA [NM_021200]
5.359 up 371
A_32_P224522 SLC25A23
Homo sapiens solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 (SLC25A23), 
mRNA [NM_024103]
4.070 up 372
A_23_P20427 RHOBTB2 Homo sapiens Rho-related BTB domain containing 2 (RHOBTB2), transcript variant 3, mRNA [NM_015178] 5.691 up 373
A_23_P375922 COL19A1 Homo sapiens collagen, type XIX, alpha 1 (COL19A1), mRNA [NM_001858] 3.951 up 374
A_21_P0009429 lnc-NEDD4L-2 Homo sapiens cDNA FLJ45655 fis, clone CTONG2012425. [AK127562] 3.445 up 375
A_32_P167705 AGBL2 Homo sapiens ATP/GTP binding protein-like 2 (AGBL2), mRNA [NM_024783] 4.125 up 376
A_24_P211565 C1QTNF6




Homo sapiens leukocyte immunoglobulin-like receptor pseudogene 2 (LILRP2), non-coding RNA 
[NR_003061]
4.201 up 378
A_24_P157370 IL17RB Homo sapiens interleukin 17 receptor B (IL17RB), mRNA [NM_018725] 4.447 up 379
A_24_P13083 TSPAN18 Homo sapiens tetraspanin 18 (TSPAN18), mRNA [NM_130783] 3.167 up 380
A_33_P3413038 PLXNB3 Homo sapiens plexin B3 (PLXNB3), transcript variant 2, mRNA [NM_001163257] 3.116 up 381
A_19_P00318174 LOC100506014 0 3.110 up 382
A_19_P00802098 LOC100506014 0 3.989 up 383
A_33_P3367112 lnc-SIRT4-1 602713021F1 NIH_MGC_48 Homo sapiens cDNA clone IMAGE:4853452 5', mRNA sequence [BG758909] 3.296 up 384
A_19_P00322432 LOC100506014 0 3.231 up 385
A_19_P00316666 LOC100506014 0 3.359 up 386
A_21_P0007481 LINC00944
Homo sapiens long intergenic non-protein coding RNA 944 (LINC00944), long non-coding RNA 
[NR_033878]
3.629 up 387
A_23_P9255 SYK Homo sapiens spleen tyrosine kinase (SYK), transcript variant 1, mRNA [NM_003177] 4.092 up 388
A_21_P0000642 LINC00959




Homo sapiens long intergenic non-protein coding RNA 959 (LINC00959), long non-coding RNA 
[NR_034125]
3.220 up 390
A_23_P20852 AUH Homo sapiens AU RNA binding protein/enoyl-CoA hydratase (AUH), mRNA [NM_001698] 3.760 up 391
A_21_P0013825 STAU2
Homo sapiens staufen double-stranded RNA binding protein 2 (STAU2), transcript variant 1, mRNA 
[NM_001164380]
3.103 up 392
A_23_P364766 SLX4IP Homo sapiens SLX4 interacting protein (SLX4IP), mRNA [NM_001009608] 6.415 up 393
A_21_P0000893 IQCH-AS1 Homo sapiens IQCH antisense RNA 1 (IQCH-AS1), transcript variant 1, long non-coding RNA [NR_040051] 7.245 up 394
A_24_P143686 SPIDR








Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like (DDX60L), transcript variant 1, mRNA 
[NM_001012967]
4.454 up 397
A_23_P258251 ENOX2 Homo sapiens ecto-NOX disulfide-thiol exchanger 2 (ENOX2), transcript variant 2, mRNA [NM_182314] 3.714 up 398
A_23_P93499 TFB1M Homo sapiens transcription factor B1, mitochondrial (TFB1M), mRNA [NM_016020] 4.198 up 399
A_33_P3214456 PDSS2 Homo sapiens prenyl (decaprenyl) diphosphate synthase, subunit 2 (PDSS2), mRNA [NM_020381] 3.909 up 400
A_23_P134167 PDSS2 Homo sapiens prenyl (decaprenyl) diphosphate synthase, subunit 2 (PDSS2), mRNA [NM_020381] 5.249 up 401
A_23_P382043 NT5DC1 Homo sapiens 5'-nucleotidase domain containing 1 (NT5DC1), mRNA [NM_152729] 3.295 up 402
A_33_P3324904 na 0 3.236 up 403
A_23_P401700 APBB1IP
Homo sapiens amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 
(APBB1IP), mRNA [NM_019043]
4.277 up 404
A_24_P32520 RNF214 Homo sapiens ring finger protein 214 (RNF214), transcript variant 1, mRNA [NM_001077239] 3.271 up 405
A_23_P55948 PRR12 Homo sapiens proline rich 12 (PRR12), mRNA [NM_020719] 3.114 up 406
A_24_P379512 PIGK Homo sapiens phosphatidylinositol glycan anchor biosynthesis, class K (PIGK), mRNA [NM_005482] 4.943 up 407
A_24_P759674 OBFC1 Homo sapiens oligonucleotide/oligosaccharide-binding fold containing 1 (OBFC1), mRNA [NM_024928] 3.204 up 408
A_24_P45451 SLAMF6 Homo sapiens SLAM family member 6 (SLAMF6), transcript variant 2, mRNA [NM_052931] 4.857 up 409
A_33_P3303857 SLAMF6 Homo sapiens SLAM family member 6 (SLAMF6), transcript variant 1, mRNA [NM_001184714] 4.605 up 410
A_23_P201319 DISP1 Homo sapiens dispatched homolog 1 (Drosophila) (DISP1), mRNA [NM_032890] 5.283 up 411
A_23_P133075 TBCK Homo sapiens TBC1 domain containing kinase (TBCK), transcript variant 4, mRNA [NM_033115] 3.324 up 412
A_23_P433369 HEATR5A Homo sapiens HEAT repeat containing 5A (HEATR5A), mRNA [NM_015473] 4.292 up 413
A_23_P412186 ZNF252P Homo sapiens zinc finger protein 252, pseudogene (ZNF252P), non-coding RNA [NR_023392] 4.083 up 414
A_23_P156390 JAKMIP2




















Homo sapiens solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 (SLC24A1), 
transcript variant 1, mRNA [NM_004727]
3.435 up 420
A_23_P126605 TMOD4 Homo sapiens tropomodulin 4 (muscle) (TMOD4), mRNA [NM_013353] 3.336 up 421
A_33_P3251332 HEATR5A Homo sapiens HEAT repeat containing 5A (HEATR5A), mRNA [NM_015473] 4.693 up 422
A_21_P0010661 XLOC_l2_001196 BROAD Institute lincRNA (XLOC_l2_001196), lincRNA [TCONS_l2_00001624] 3.220 up 423
A_24_P860797 PAIP2B Homo sapiens poly(A) binding protein interacting protein 2B (PAIP2B), mRNA [NM_020459] 6.717 up 424
A_23_P133279 FAM173B
Homo sapiens family with sequence similarity 173, member B (FAM173B), transcript variant 1, mRNA 
[NM_199133]
5.741 up 425
A_33_P3384078 AK9 Homo sapiens cDNA FLJ16163 fis, clone BRCAN2014229. [AK131244] 4.356 up 426
A_24_P678418 DICER1-AS1 Homo sapiens DICER1 antisense RNA 1 (DICER1-AS1), long non-coding RNA [NR_015415] 5.360 up 427
A_23_P356526 TRIM5 Homo sapiens tripartite motif containing 5 (TRIM5), transcript variant gamma, mRNA [NM_033092] 4.729 up 428
A_24_P141629 FAM111A




Homo sapiens GTPase, very large interferon inducible pseudogene 1 (GVINP1), non-coding RNA 
[NR_003945]
5.417 up 430
A_23_P384056 CCDC14 Homo sapiens coiled-coil domain containing 14 (CCDC14), mRNA [NM_022757] 5.218 up 431
A_33_P3394234 ZNF133 Homo sapiens zinc finger protein 133 (ZNF133), transcript variant 1, mRNA [NM_003434] 4.354 up 432
A_32_P209960 CIITA
Homo sapiens class II, major histocompatibility complex, transactivator (CIITA), transcript variant 2, mRNA 
[NM_000246]
5.437 up 433
A_33_P3421351 TRAF3IP3 Homo sapiens TRAF3 interacting protein 3 (TRAF3IP3), transcript variant 2, mRNA [NM_001287754] 3.563 up 434
A_33_P3336622 ALDH3A2




Homo sapiens solute carrier family 38, member 10 (SLC38A10), transcript variant 1, mRNA 
[NM_001037984]
3.571 up 436
A_23_P146111 NIPAL2 Homo sapiens NIPA-like domain containing 2 (NIPAL2), mRNA [NM_024759] 4.230 up 437
A_33_P3398448 PARP10 Homo sapiens poly (ADP-ribose) polymerase family, member 10 (PARP10), mRNA [NM_032789] 3.939 up 438
A_23_P127367 POLD4








Homo sapiens methylthioribose-1-phosphate isomerase 1 (MRI1), transcript variant 1, mRNA 
[NM_001031727]
4.936 up 441
A_24_P329065 BTN3A1 Homo sapiens butyrophilin, subfamily 3, member A1 (BTN3A1), transcript variant 1, mRNA [NM_007048] 3.574 up 442
A_24_P252078 BTN3A2 Homo sapiens butyrophilin, subfamily 3, member A2 (BTN3A2), transcript variant 1, mRNA [NM_007047] 4.132 up 443
A_23_P155376 CRELD1 Homo sapiens cysteine-rich with EGF-like domains 1 (CRELD1), transcript variant 2, mRNA [NM_015513] 3.111 up 444
A_23_P390172 RNASEL
Homo sapiens ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) (RNASEL), mRNA 
[NM_021133]
4.402 up 445
A_32_P14610 PDLIM5 Homo sapiens PDZ and LIM domain 5 (PDLIM5), transcript variant 1, mRNA [NM_006457] 4.654 up 446
A_23_P369666 ZMYND8 zinc finger, MYND-type containing 8 [Source:HGNC Symbol;Acc:HGNC:9397] [ENST00000468376] 3.159 up 447
A_33_P3416881 C2orf27A Homo sapiens chromosome 2 open reading frame 27A (C2orf27A), mRNA [NM_013310] 4.206 up 448
A_21_P0000682 LHX4-AS1 Homo sapiens LHX4 antisense RNA 1 (LHX4-AS1), long non-coding RNA [NR_037642] 3.174 up 449
A_23_P34644 FCGR2B
Homo sapiens Fc fragment of IgG, low affinity IIb, receptor (CD32) (FCGR2B), transcript variant 1, mRNA 
[NM_004001]
4.806 up 450
A_33_P3418170 DDX58 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (DDX58), mRNA [NM_014314] 3.339 up 451
A_33_P3252499 CFAP44
Homo sapiens cilia and flagella associated protein 44 (CFAP44), transcript variant 1, mRNA 
[NM_001164496]
3.228 up 452
A_32_P213661 CCDC122 Homo sapiens coiled-coil domain containing 122 (CCDC122), mRNA [NM_144974] 3.689 up 453
A_23_P501877 ZFP64 Homo sapiens ZFP64 zinc finger protein (ZFP64), transcript variant 1, mRNA [NM_018197] 3.524 up 454
A_33_P3317880 ZNF252P Homo sapiens zinc finger protein 252, pseudogene (ZNF252P), non-coding RNA [NR_023392] 4.553 up 455
A_23_P82047 STXBP5 Homo sapiens syntaxin binding protein 5 (tomosyn) (STXBP5), transcript variant 2, mRNA [NM_001127715] 3.101 up 456
A_23_P425304 SUFU Homo sapiens suppressor of fused homolog (Drosophila) (SUFU), transcript variant 1, mRNA [NM_016169] 3.413 up 457
A_33_P3369058 LRRK2 Homo sapiens leucine-rich repeat kinase 2 (LRRK2), mRNA [NM_198578] 4.240 up 458
A_21_P0000049 DISC1 Homo sapiens disrupted in schizophrenia 1 (DISC1), transcript variant b, mRNA [NM_001164538] 3.451 up 459
A_23_P336198 GLCCI1 Homo sapiens glucocorticoid induced transcript 1 (GLCCI1), mRNA [NM_138426] 4.648 up 460
A_21_P0014183 LOC100505921 Homo sapiens uncharacterized LOC100505921 (LOC100505921), long non-coding RNA [NR_110018] 3.408 up 461
A_33_P3253687 GVINP1
Homo sapiens GTPase, very large interferon inducible pseudogene 1 (GVINP1), non-coding RNA 
[NR_003945]
6.823 up 462
A_24_P349196 CCDC30 Homo sapiens coiled-coil domain containing 30 (CCDC30), mRNA [NM_001080850] 4.552 up 463
A_23_P381714 CA13 Homo sapiens carbonic anhydrase XIII (CA13), mRNA [NM_198584] 5.394 up 464
A_23_P78595 CEACAM21
Homo sapiens carcinoembryonic antigen-related cell adhesion molecule 21 (CEACAM21), transcript variant 
2, mRNA [NM_033543]
3.124 up 465
A_24_P945228 CYP4V2 Homo sapiens cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2), mRNA [NM_207352] 4.436 up 466
A_33_P3219840 ZNRD1-AS1 Homo sapiens ZNRD1 antisense RNA 1 (ZNRD1-AS1), long non-coding RNA [NR_026751] 3.762 up 467
A_33_P3373348 AFF3 AF4/FMR2 family, member 3 [Source:HGNC Symbol;Acc:HGNC:6473] [ENST00000483600] 3.155 up 468
A_21_P0014736 LOC100506538 PREDICTED: Homo sapiens uncharacterized LOC100506538 (LOC100506538), ncRNA [XR_426345] 3.112 up 469
A_21_P0006615 na 0 5.478 up 470
A_33_P3268838 CPEB1
Homo sapiens cytoplasmic polyadenylation element binding protein 1 (CPEB1), transcript variant 5, mRNA 
[NM_001288819]
3.309 up 471
A_24_P712562 C17orf67 Homo sapiens chromosome 17 open reading frame 67 (C17orf67), mRNA [NM_001085430] 3.304 up 472
A_23_P382705 TMTC2 Homo sapiens transmembrane and tetratricopeptide repeat containing 2 (TMTC2), mRNA [NM_152588] 3.305 up 473
A_23_P24716 TMEM132A Homo sapiens transmembrane protein 132A (TMEM132A), transcript variant 1, mRNA [NM_017870] 3.857 up 474
A_21_P0005688 lnc-RP11-150O12.5.1-2LNCipedia lincRNA (lnc-RP11-150O12.5.1-2), lincRNA [lnc-RP11-150O12.5.1-2:1] 4.168 up 475
A_23_P109452 CHEK2 Homo sapiens checkpoint kinase 2 (CHEK2), transcript variant 3, mRNA [NM_001005735] 3.781 up 476
A_33_P3221999 GSDMB Homo sapiens gasdermin B (GSDMB), transcript variant 3, mRNA [NM_001165958] 3.211 up 477
A_23_P153524 C19orf73 Homo sapiens chromosome 19 open reading frame 73 (C19orf73), mRNA [NM_018111] 3.302 up 478
A_33_P3335522 FCRL5 Homo sapiens Fc receptor-like 5 (FCRL5), transcript variant 2, mRNA [NM_001195388] 3.174 up 479
A_24_P290751 DTX1 Homo sapiens deltex 1, E3 ubiquitin ligase (DTX1), mRNA [NM_004416] 5.928 up 480
A_23_P204998 FARP1
Homo sapiens FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived) (FARP1), 
transcript variant 1, mRNA [NM_005766]
3.297 up 481
A_23_P71624 PAX5 Homo sapiens paired box 5 (PAX5), transcript variant 1, mRNA [NM_016734] 3.171 up 482
A_23_P373464 AFF3 Homo sapiens AF4/FMR2 family, member 3 (AFF3), transcript variant 1, mRNA [NM_002285] 3.252 up 483
A_33_P3350259 FAM129C




Homo sapiens family with sequence similarity 129, member C (FAM129C), transcript variant 1, mRNA 
[NM_173544]
3.534 up 485
A_24_P206317 HDAC9 Homo sapiens histone deacetylase 9 (HDAC9), transcript variant 1, mRNA [NM_058176] 4.792 up 486
A_23_P404162 HDAC9 Homo sapiens histone deacetylase 9 (HDAC9), transcript variant 3, mRNA [NM_014707] 3.916 up 487
A_23_P303803 C19orf18 Homo sapiens chromosome 19 open reading frame 18 (C19orf18), mRNA [NM_152474] 3.732 up 488
A_21_P0011696 LINC00665
Homo sapiens long intergenic non-protein coding RNA 665 (LINC00665), transcript variant 2, long non-
coding RNA [NR_038279]
4.408 up 489
A_23_P214208 CNR1 Homo sapiens cannabinoid receptor 1 (brain) (CNR1), transcript variant 2, mRNA [NM_033181] 5.830 up 490
A_23_P252155 STRBP
Homo sapiens spermatid perinuclear RNA binding protein (STRBP), transcript variant 1, mRNA 
[NM_018387]
3.272 up 491
A_24_P64344 BLNK Homo sapiens B-cell linker (BLNK), transcript variant 1, mRNA [NM_013314] 5.093 up 492
A_33_P3363637 BLNK Homo sapiens B-cell linker (BLNK), transcript variant 1, mRNA [NM_013314] 4.897 up 493
A_23_P41194 LRRC34 Homo sapiens leucine rich repeat containing 34 (LRRC34), transcript variant 3, mRNA [NM_153353] 3.962 up 494
A_21_P0000091 LRRC34 Homo sapiens leucine rich repeat containing 34 (LRRC34), transcript variant 1, mRNA [NM_001172780] 3.250 up 495
A_33_P3406567 MS4A1
Homo sapiens membrane-spanning 4-domains, subfamily A, member 1 (MS4A1), transcript variant 1, 
mRNA [NM_152866]
3.723 up 496
A_23_P370830 KLHL14 Homo sapiens kelch-like family member 14 (KLHL14), mRNA [NM_020805] 3.278 up 497
A_24_P694820 lnc-ZNF236-1 LNCipedia lincRNA (lnc-ZNF236-1), lincRNA [lnc-ZNF236-1:5] 8.274 up 498
A_23_P147245 OSBPL10 Homo sapiens oxysterol binding protein-like 10 (OSBPL10), transcript variant 1, mRNA [NM_017784] 3.552 up 499
A_23_P312920 POU2AF1 Homo sapiens POU class 2 associating factor 1 (POU2AF1), mRNA [NM_006235] 3.726 up 500
A_33_P3335511 FCRL5 Homo sapiens Fc receptor-like 5 (FCRL5), transcript variant 2, mRNA [NM_001195388] 5.250 up 501
A_21_P0010658 FCRL5 Homo sapiens Fc receptor-like 5 (FCRL5), transcript variant 2, mRNA [NM_001195388] 4.522 up 502
A_33_P3335525 FCRL5 Fc receptor-like 5 [Source:HGNC Symbol;Acc:HGNC:18508] [ENST00000368189] 4.960 up 503
A_33_P3335506 FCRL5 Fc receptor-like 5 [Source:HGNC Symbol;Acc:HGNC:18508] [ENST00000368190] 5.355 up 504
A_23_P201211 FCRL5 Homo sapiens Fc receptor-like 5 (FCRL5), transcript variant 1, mRNA [NM_031281] 6.043 up 505
A_21_P0010993 LOC101929174 PREDICTED: Homo sapiens uncharacterized LOC101929174 (LOC101929174), ncRNA [XR_424270] 4.341 up 506
A_21_P0010991 LOC101929174 PREDICTED: Homo sapiens uncharacterized LOC101929174 (LOC101929174), ncRNA [XR_424270] 3.575 up 507
A_21_P0000840 PXN-AS1 Homo sapiens PXN antisense RNA 1 (PXN-AS1), long non-coding RNA [NR_038924] 3.780 up 508
A_33_P3340655 KLHL32 Homo sapiens kelch-like family member 32 (KLHL32), transcript variant 1, mRNA [NM_052904] 3.354 up 509
A_24_P374634 STAU2
Homo sapiens staufen double-stranded RNA binding protein 2 (STAU2), transcript variant 1, mRNA 
[NM_001164380]
3.296 up 510
A_23_P82351 BBS9 Homo sapiens Bardet-Biedl syndrome 9 (BBS9), transcript variant 2, mRNA [NM_198428] 3.319 up 511
A_33_P3234764 na Homo sapiens cDNA FLJ27410 fis, clone WMC04875. [AK130920] 3.250 up 512
A_21_P0010989 XLOC_l2_002433 BROAD Institute lincRNA (XLOC_l2_002433), lincRNA [TCONS_l2_00004704] 3.238 up 513
A_23_P143981 FBLN2 Homo sapiens fibulin 2 (FBLN2), transcript variant 1, mRNA [NM_001004019] 4.990 up 514
A_23_P21495 FCGBP Homo sapiens Fc fragment of IgG binding protein (FCGBP), mRNA [NM_003890] 4.944 up 515
A_23_P98645 DCHS1 Homo sapiens dachsous cadherin-related 1 (DCHS1), mRNA [NM_003737] 3.800 up 516
A_23_P110941 GSTA4 Homo sapiens glutathione S-transferase alpha 4 (GSTA4), mRNA [NM_001512] 4.308 up 517
A_33_P3257903 GSTA4 Homo sapiens glutathione S-transferase alpha 4 (GSTA4), mRNA [NM_001512] 5.687 up 518
A_24_P178631 na Homo sapiens cDNA FLJ14761 fis, clone NT2RP3003302. [AK027667] 5.086 up 519
A_24_P149124 NREP Homo sapiens neuronal regeneration related protein (NREP), transcript variant 1, mRNA [NM_004772] 7.061 up 520
A_33_P3391290 NREP
Homo sapiens neuronal regeneration related protein (NREP), transcript variant 11, mRNA 
[NM_001142483]
6.475 up 521
A_33_P3287907 ZBED3-AS1 Homo sapiens ZBED3 antisense RNA 1 (ZBED3-AS1), long non-coding RNA [NR_024398] 4.519 up 522
A_21_P0004869 LOC100131289 Homo sapiens uncharacterized LOC100131289 (LOC100131289), long non-coding RNA [NR_038929] 11.701 up 523
A_32_P74752 LOC100131289 Homo sapiens uncharacterized LOC100131289 (LOC100131289), long non-coding RNA [NR_038929] 8.340 up 524
A_21_P0009669 lnc-ZNF682-1 LNCipedia lincRNA (lnc-ZNF682-1), lincRNA [lnc-ZNF682-1:1] 3.286 up 525
A_33_P3213962 OR13A1 Homo sapiens olfactory receptor, family 13, subfamily A, member 1 (OR13A1), mRNA [NM_001004297] 6.106 up 526
A_23_P328034 C20orf96
















Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, beta (PIP5K1B), transcript variant 3, 
mRNA [NM_001278253]
8.483 up 531
A_24_P349965 TCF19 Homo sapiens transcription factor 19 (TCF19), transcript variant 1, mRNA [NM_007109] 4.533 up 532
A_23_P31765 PKIA
Homo sapiens protein kinase (cAMP-dependent, catalytic) inhibitor alpha (PKIA), transcript variant 1, 
mRNA [NM_006823]
3.599 up 533
A_23_P316150 IFT80 Homo sapiens intraflagellar transport 80 (IFT80), transcript variant 1, mRNA [NM_020800] 3.452 up 534
A_24_P943613 TBC1D1
Homo sapiens TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 (TBC1D1), transcript variant 1, 
mRNA [NM_015173]
3.482 up 535
A_24_P365365 TCF3 Homo sapiens transcription factor 3 (TCF3), transcript variant 1, mRNA [NM_003200] 3.286 up 536
A_33_P3369844 CD24 Homo sapiens CD24 molecule (CD24), transcript variant 1, mRNA [NM_013230] 4.024 up 537
A_24_P941625 ZNF70 Homo sapiens zinc finger protein 70 (ZNF70), mRNA [NM_021916] 5.370 up 538
A_23_P57417 MMP11 Homo sapiens matrix metallopeptidase 11 (stromelysin 3) (MMP11), mRNA [NM_005940] 6.973 up 539
A_32_P90483 STXBP4 Homo sapiens syntaxin binding protein 4 (STXBP4), mRNA [NM_178509] 3.469 up 540
A_24_P284584 ZNF559 Homo sapiens zinc finger protein 559 (ZNF559), transcript variant 2, mRNA [NM_032497] 3.940 up 541
A_33_P3234989 IFT81 Homo sapiens intraflagellar transport 81 (IFT81), transcript variant 1, mRNA [NM_014055] 6.803 up 542
A_21_P0014472 na
ALU1_HUMAN (P39188) Alu subfamily J sequence contamination warning entry, partial (13%) 
[THC2757892]
5.306 up 543
A_23_P357717 TCL1A Homo sapiens T-cell leukemia/lymphoma 1A (TCL1A), transcript variant 1, mRNA [NM_021966] 7.591 up 544
A_23_P125618 GABRA3 Homo sapiens gamma-aminobutyric acid (GABA) A receptor, alpha 3 (GABRA3), mRNA [NM_000808] 3.886 up 545
A_19_P00806490 TET1 Homo sapiens tet methylcytosine dioxygenase 1 (TET1), mRNA [NM_030625] 4.225 up 546
A_23_P38154 FDXR Homo sapiens ferredoxin reductase (FDXR), transcript variant 2, mRNA [NM_004110] 3.356 up 547
A_21_P0014820 na endogenous retrovirus group K3, member 1 [Source:HGNC Symbol;Acc:HGNC:30466] [ENST00000413518] 3.857 up 548
A_32_P175715 MEIG1 Homo sapiens meiosis/spermiogenesis associated 1 (MEIG1), mRNA [NM_001080836] 4.969 up 549
A_23_P212241 CHL1 Homo sapiens cell adhesion molecule L1-like (CHL1), transcript variant 1, mRNA [NM_006614] 8.090 up 550
A_21_P0009109 lnc-FAM65A-1 LNCipedia lincRNA (lnc-FAM65A-1), lincRNA [lnc-FAM65A-1:1] 3.722 up 551
A_21_P0010270 na 0 8.706 up 552
A_21_P0010269 lnc-AF165138.7.1-3 LNCipedia lincRNA (lnc-AF165138.7.1-3), lincRNA [lnc-AF165138.7.1-3:2] 4.246 up 553
A_33_P3273723 na Homo sapiens cDNA FLJ26029 fis, clone PNC05018. [AK129540] 3.124 up 554
A_33_P3288824 H2AFB3 Homo sapiens H2A histone family, member B3 (H2AFB3), mRNA [NM_080720] 3.158 up 555
A_21_P0013802 TMLHE Homo sapiens trimethyllysine hydroxylase, epsilon (TMLHE), transcript variant 1, mRNA [NM_018196] 4.118 up 556
A_23_P348281 TCEANC2








Homo sapiens B-cell scaffold protein with ankyrin repeats 1 (BANK1), transcript variant 1, mRNA 
[NM_017935]
3.758 up 559
A_23_P392476 AK9 Homo sapiens adenylate kinase 9 (AK9), transcript variant 1, mRNA [NM_001145128] 3.717 up 560
A_23_P313632 FUT8
Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (FUT8), transcript variant 1, mRNA 
[NM_178155]
4.143 up 561
A_23_P328621 UBQLNL Homo sapiens ubiquilin-like (UBQLNL), mRNA [NM_145053] 3.901 up 562
A_23_P24623 ELP4








Homo sapiens branched chain keto acid dehydrogenase E1, beta polypeptide (BCKDHB), transcript variant 
2, mRNA [NM_000056]
4.522 up 565
A_23_P33720 FARS2 Homo sapiens phenylalanyl-tRNA synthetase 2, mitochondrial (FARS2), mRNA [NM_006567] 3.493 up 566
A_24_P72518 AHCYL2 Homo sapiens adenosylhomocysteinase-like 2 (AHCYL2), transcript variant 1, mRNA [NM_015328] 3.813 up 567
A_24_P194886 EHBP1 Homo sapiens EH domain binding protein 1 (EHBP1), transcript variant 1, mRNA [NM_015252] 3.625 up 568
A_24_P71244 PIK3CD




Homo sapiens protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) (POMGNT1), 
transcript variant 2, mRNA [NM_001243766]
3.158 up 570
A_23_P136196 TBC1D19 Homo sapiens TBC1 domain family, member 19 (TBC1D19), transcript variant 1, mRNA [NM_018317] 3.943 up 571
A_32_P71113 SCAI Homo sapiens suppressor of cancer cell invasion (SCAI), transcript variant 1, mRNA [NM_173690] 3.795 up 572
A_23_P133359 ZFP2 Homo sapiens ZFP2 zinc finger protein (ZFP2), mRNA [NM_030613] 5.540 up 573
A_23_P126757 INTS3 Homo sapiens integrator complex subunit 3 (INTS3), mRNA [NM_023015] 3.681 up 574
A_23_P140427 EVL Homo sapiens Enah/Vasp-like (EVL), mRNA [NM_016337] 4.564 up 575
A_23_P54556 MKL2 Homo sapiens MKL/myocardin-like 2 (MKL2), mRNA [NM_014048] 4.805 up 576
A_23_P33154 STAU2
Homo sapiens staufen double-stranded RNA binding protein 2 (STAU2), transcript variant 5, mRNA 
[NM_014393]
4.333 up 577
A_23_P97810 na poly (ADP-ribose) glycohydrolase [Source:HGNC Symbol;Acc:HGNC:8605] [ENST00000614063] 3.191 up 578
A_23_P138125 FAIM3 Homo sapiens Fas apoptotic inhibitory molecule 3 (FAIM3), transcript variant 1, mRNA [NM_005449] 4.519 up 579
A_33_P3351101 TYSND1 Homo sapiens trypsin domain containing 1 (TYSND1), transcript variant 1, mRNA [NM_173555] 4.252 up 580
A_33_P3327333 IRF3 Homo sapiens interferon regulatory factor 3 (IRF3), transcript variant 3, mRNA [NM_001197123] 3.120 up 581
A_24_P333421 ZNF862 Homo sapiens zinc finger protein 862 (ZNF862), mRNA [NM_001099220] 3.884 up 582
A_33_P3210965 TCTN1 Homo sapiens tectonic family member 1 (TCTN1), transcript variant 1, mRNA [NM_001082538] 3.331 up 583
A_21_P0010860 LINC00202-1
Homo sapiens long intergenic non-protein coding RNA 202-1 (LINC00202-1), long non-coding RNA 
[NR_026795]
3.457 up 584
A_21_P0000702 STX18-AS1 Homo sapiens STX18 antisense RNA 1 (head to head) (STX18-AS1), long non-coding RNA [NR_037888] 3.940 up 585
A_23_P389692 KIAA1328 Homo sapiens KIAA1328 (KIAA1328), mRNA [NM_020776] 4.489 up 586
A_33_P3256425 BICD1 Homo sapiens bicaudal D homolog 1 (Drosophila) (BICD1), transcript variant 1, mRNA [NM_001714] 4.919 up 587
A_33_P3343957 EHBP1 Homo sapiens EH domain binding protein 1 (EHBP1), transcript variant 1, mRNA [NM_015252] 3.103 up 588
A_33_P3305531 METTL15 Homo sapiens methyltransferase like 15 (METTL15), transcript variant 3, mRNA [NM_001297775] 3.764 up 589
A_23_P346982 DTWD2 Homo sapiens DTW domain containing 2 (DTWD2), mRNA [NM_173666] 3.971 up 590
A_23_P14458 L3HYPDH Homo sapiens L-3-hydroxyproline dehydratase (trans-) (L3HYPDH), mRNA [NM_144581] 4.646 up 591
A_23_P436526 SLC25A42 Homo sapiens solute carrier family 25, member 42 (SLC25A42), mRNA [NM_178526] 3.274 up 592
A_19_P00319698 na KIAA1328 [Source:HGNC Symbol;Acc:HGNC:29248] [ENST00000601437] 3.499 up 593
A_32_P86245 EFHC1
Homo sapiens EF-hand domain (C-terminal) containing 1 (EFHC1), transcript variant A, mRNA 
[NM_018100]
4.187 up 594
A_32_P167471 CLMN Homo sapiens calmin (calponin-like, transmembrane) (CLMN), mRNA [NM_024734] 3.754 up 595
A_21_P0004811 lnc-AL035696.1-2 LNCipedia lincRNA (lnc-AL035696.1-2), lincRNA [lnc-AL035696.1-2:1] 10.310 up 596
A_23_P20363 ZC2HC1A Homo sapiens zinc finger, C2HC-type containing 1A (ZC2HC1A), mRNA [NM_016010] 3.265 up 597
A_21_P0014689 LOC100506974 PREDICTED: Homo sapiens uncharacterized LOC100506974 (LOC100506974), ncRNA [XR_111668] 3.121 up 598
A_23_P343900 na
immunoglobulin heavy variable 5-78 (pseudogene) [Source:HGNC Symbol;Acc:HGNC:5660] 
[ENST00000450948]
5.753 up 599
A_33_P3240182 na immunoglobulin heavy variable 5-51 [Source:HGNC Symbol;Acc:HGNC:5659] [ENST00000390626] 4.587 up 600
A_33_P3278137 RPL31P11 Homo sapiens ribosomal protein L31 pseudogene 11 (RPL31P11), non-coding RNA [NR_002595] 3.699 up 601
A_23_P205348 TCL6












Homo sapiens zinc finger with KRAB and SCAN domains 7 (ZKSCAN7), transcript variant 5, mRNA 
[NM_001288592]
4.814 up 605
A_21_P0012741 lnc-LARP1B-2 Homo sapiens cDNA FLJ41533 fis, clone BRTHA2016179. [AK123527] 3.472 up 606
A_33_P3362696 RIC8B Homo sapiens RIC8 guanine nucleotide exchange factor B (RIC8B), mRNA [NM_018157] 3.208 up 607
A_33_P3449397 METTL3 Homo sapiens methyltransferase like 3 (METTL3), mRNA [NM_019852] 3.334 up 608
A_33_P3218980 ENTPD1
Homo sapiens ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), transcript variant 1, mRNA 
[NM_001776]
3.369 up 609
A_23_P4714 MIA Homo sapiens melanoma inhibitory activity (MIA), transcript variant 1, mRNA [NM_006533] 5.170 up 610
A_23_P423482 FAM81A Homo sapiens family with sequence similarity 81, member A (FAM81A), mRNA [NM_152450] 5.927 up 611
A_33_P3299254 VPREB3 Homo sapiens pre-B lymphocyte 3 (VPREB3), mRNA [NM_013378] 5.645 up 612
A_33_P3401990 VPREB3 Homo sapiens pre-B lymphocyte 3 (VPREB3), mRNA [NM_013378] 5.531 up 613
A_33_P3236734 CLEC17A




Homo sapiens protein tyrosine phosphatase, receptor type, N polypeptide 2 (PTPRN2), transcript variant 1, 
mRNA [NM_002847]
4.862 up 615
A_23_P103803 FCRL3 Homo sapiens Fc receptor-like 3 (FCRL3), mRNA [NM_052939] 5.504 up 616
A_33_P3368334 FCRL3 Fc receptor-like 3 [Source:HGNC Symbol;Acc:HGNC:18506] [ENST00000480682] 7.939 up 617
A_23_P360804 CPNE5 Homo sapiens copine V (CPNE5), mRNA [NM_020939] 6.361 up 618
A_24_P319647 FCRL2 Homo sapiens Fc receptor-like 2 (FCRL2), transcript variant 1, mRNA [NM_030764] 5.609 up 619
A_23_P160751 FCRL2 Homo sapiens Fc receptor-like 2 (FCRL2), transcript variant 1, mRNA [NM_030764] 5.745 up 620
A_33_P3294504 FCRL1 Homo sapiens Fc receptor-like 1 (FCRL1), transcript variant 2, mRNA [NM_001159397] 3.942 up 621
A_23_P149368 FCRL1 Homo sapiens Fc receptor-like 1 (FCRL1), transcript variant 1, mRNA [NM_052938] 5.905 up 622
A_23_P208182 SIGLEC10 Homo sapiens sialic acid binding Ig-like lectin 10 (SIGLEC10), transcript variant 1, mRNA [NM_033130] 3.303 up 623
A_23_P156562 CRIP3 Homo sapiens cysteine-rich protein 3 (CRIP3), mRNA [NM_206922] 4.784 up 624
A_21_P0012439 TRANK1 Homo sapiens tetratricopeptide repeat and ankyrin repeat containing 1 (TRANK1), mRNA [NM_014831] 3.205 up 625
A_33_P3306823 ZNF846 Homo sapiens zinc finger protein 846 (ZNF846), mRNA [NM_001077624] 3.774 up 626
A_33_P3337981 FIG4 Homo sapiens FIG4 phosphoinositide 5-phosphatase (FIG4), mRNA [NM_014845] 3.764 up 627
A_21_P0002653 ASXL2
additional sex combs like transcriptional regulator 2 [Source:HGNC Symbol;Acc:HGNC:23805] 
[ENST00000435504]
3.398 up 628
A_23_P311640 AGFG2 Homo sapiens ArfGAP with FG repeats 2 (AGFG2), mRNA [NM_006076] 3.636 up 629
A_21_P0012221 ANKRD20A11P
Homo sapiens ankyrin repeat domain 20 family, member A11, pseudogene (ANKRD20A11P), non-coding 
RNA [NR_027270]
3.204 up 630
A_23_P209799 MYO7B Homo sapiens myosin VIIB (MYO7B), mRNA [NM_001080527] 4.700 up 631
A_32_P161033 lnc-RP3-377D14.1.1-3Homo sapiens, clone IMAGE:6155889, mRNA. [BC043411] 4.307 up 632
A_23_P21673 FOCAD Homo sapiens focadhesin (FOCAD), mRNA [NM_017794] 3.909 up 633
A_21_P0014186 LOC101927811
Homo sapiens uncharacterized LOC101927811 (LOC101927811), transcript variant 1, long non-coding RNA 
[NR_110119]
4.547 up 634
A_23_P152047 SCAMP5 Homo sapiens secretory carrier membrane protein 5 (SCAMP5), transcript variant 3, mRNA [NM_138967] 3.946 up 635
A_33_P3211968 lnc-TCL1B-2
human full-length cDNA clone CS0DG006YJ19 of B cells (Ramos cell line) of Homo sapiens (human). 
[BX247990]
6.978 up 636
A_21_P0000769 LOC100505622 Homo sapiens uncharacterized LOC100505622 (LOC100505622), long non-coding RNA [NR_038332] 3.159 up 637
A_33_P3421728 DGKG Homo sapiens diacylglycerol kinase, gamma 90kDa (DGKG), transcript variant 1, mRNA [NM_001346] 3.819 up 638
A_33_P3366175 LOC100130298 Homo sapiens hCG1816373-like (LOC100130298), long non-coding RNA [NR_034003] 4.806 up 639
A_32_P167904 ZNF681 Homo sapiens zinc finger protein 681 (ZNF681), mRNA [NM_138286] 4.404 up 640
A_33_P3226212 JAM2 Homo sapiens junctional adhesion molecule 2 (JAM2), transcript variant 3, mRNA [NM_001270408] 7.402 up 641
A_21_P0014373 lnc-ZNF667-2 Homo sapiens mRNA; cDNA DKFZp686A1999 (from clone DKFZp686A1999). [BX647249] 3.541 up 642
A_33_P3336587 LOC283710 Homo sapiens uncharacterized LOC283710 (LOC283710), mRNA [NM_001243538] 5.461 up 643
A_33_P3482534 LOC613266 Homo sapiens hypothetical LOC613266, mRNA (cDNA clone IMAGE:5222345). [BC043571] 4.954 up 644
A_23_P121396 DNAJC19
Homo sapiens DnaJ (Hsp40) homolog, subfamily C, member 19 (DNAJC19), transcript variant 1, mRNA 
[NM_145261]
3.897 up 645
A_33_P3231367 ATXN10 Homo sapiens ataxin 10 (ATXN10), transcript variant 1, mRNA [NM_013236] 4.113 up 646
A_24_P142269 HIRIP3 Homo sapiens HIRA interacting protein 3 (HIRIP3), transcript variant 1, mRNA [NM_003609] 4.269 up 647
A_23_P91487 RWDD2B Homo sapiens RWD domain containing 2B (RWDD2B), mRNA [NM_016940] 4.816 up 648
A_23_P151368 N6AMT2 Homo sapiens N-6 adenine-specific DNA methyltransferase 2 (putative) (N6AMT2), mRNA [NM_174928] 6.011 up 649
A_23_P97736 NCDN Homo sapiens neurochondrin (NCDN), transcript variant 3, mRNA [NM_014284] 6.451 up 650
A_33_P3368301 BOLA3 Homo sapiens bolA family member 3 (BOLA3), transcript variant 1, mRNA [NM_212552] 3.941 up 651
A_23_P42802 PDIA4 Homo sapiens protein disulfide isomerase family A, member 4 (PDIA4), mRNA [NM_004911] 3.683 up 652
A_23_P102517 PDE6D
Homo sapiens phosphodiesterase 6D, cGMP-specific, rod, delta (PDE6D), transcript variant 1, mRNA 
[NM_002601]
4.271 up 653
A_23_P211850 ABHD6 Homo sapiens abhydrolase domain containing 6 (ABHD6), mRNA [NM_020676] 4.557 up 654
A_23_P149813 RSU1 Homo sapiens Ras suppressor protein 1 (RSU1), transcript variant 1, mRNA [NM_012425] 3.256 up 655
A_23_P318604 CYHR1 cysteine/histidine-rich 1 [Source:HGNC Symbol;Acc:HGNC:17806] [ENST00000528663] 3.824 up 656
A_23_P97221 ZNF691 Homo sapiens zinc finger protein 691 (ZNF691), transcript variant 2, mRNA [NM_015911] 3.276 up 657
A_23_P120931 APOBEC3C




Homo sapiens apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F (APOBEC3F), transcript 
variant 1, mRNA [NM_145298]
3.868 up 659
A_23_P37144 DTD2 Homo sapiens D-tyrosyl-tRNA deacylase 2 (putative) (DTD2), mRNA [NM_080664] 3.327 up 660
A_23_P95823 NSMCE1 Homo sapiens non-SMC element 1 homolog (S. cerevisiae) (NSMCE1), mRNA [NM_145080] 3.826 up 661
A_33_P3215059 NSMCE1 Homo sapiens non-SMC element 1 homolog (S. cerevisiae) (NSMCE1), mRNA [NM_145080] 3.386 up 662
A_23_P216630 SLC44A1
Homo sapiens solute carrier family 44 (choline transporter), member 1 (SLC44A1), transcript variant 1, 
mRNA [NM_080546]
3.158 up 663
A_23_P65830 HDDC3 Homo sapiens HD domain containing 3 (HDDC3), transcript variant 2, mRNA [NM_198527] 3.204 up 664
A_23_P15305 PRPSAP1
Homo sapiens phosphoribosyl pyrophosphate synthetase-associated protein 1 (PRPSAP1), mRNA 
[NM_002766]
4.139 up 665
A_24_P57730 MRPL52 Homo sapiens mitochondrial ribosomal protein L52 (MRPL52), transcript variant 4, mRNA [NM_181304] 6.435 up 666
A_23_P97932 MSRB2 Homo sapiens methionine sulfoxide reductase B2 (MSRB2), mRNA [NM_012228] 3.522 up 667
A_24_P818529 na ribonuclease H2, subunit C pseudogene 1 [Source:HGNC Symbol;Acc:HGNC:24117] [ENST00000454281] 3.192 up 668
A_23_P166248 RCAN1 Homo sapiens regulator of calcineurin 1 (RCAN1), transcript variant 1, mRNA [NM_004414] 3.599 up 669
A_24_P192805 CARD17 Homo sapiens caspase recruitment domain family, member 17 (CARD17), mRNA [NM_001007232] 3.362 up 670
A_23_P92261 ECE2 Homo sapiens endothelin converting enzyme 2 (ECE2), transcript variant 3, mRNA [NM_032331] 3.172 up 671
A_24_P184388 LRTOMT
Homo sapiens leucine rich transmembrane and O-methyltransferase domain containing (LRTOMT), 
transcript variant 1, mRNA [NM_145309]
4.114 up 672
A_33_P3286046 DPCD Homo sapiens deleted in primary ciliary dyskinesia homolog (mouse) (DPCD), mRNA [NM_015448] 3.133 up 673
A_23_P252201 EAF2 Homo sapiens ELL associated factor 2 (EAF2), mRNA [NM_018456] 3.601 up 674
A_23_P3602 NUDT7




Homo sapiens long intergenic non-protein coding RNA 1504 (LINC01504), transcript variant 2, long non-
coding RNA [NR_110953]
3.537 up 676
A_23_P125668 SLC25A43 Homo sapiens solute carrier family 25, member 43 (SLC25A43), mRNA [NM_145305] 3.260 up 677
A_33_P3386765 ABHD14A Homo sapiens abhydrolase domain containing 14A (ABHD14A), mRNA [NM_015407] 3.882 up 678
A_33_P3283713 ABHD14A Homo sapiens abhydrolase domain containing 14A (ABHD14A), mRNA [NM_015407] 3.498 up 679
A_33_P3353816 ITGA4




Homo sapiens integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) (ITGA4), mRNA 
[NM_000885]
3.382 up 681
A_24_P306443 LOC100233156 Homo sapiens tektin 4 pseudogene (LOC100233156), transcript variant 1, non-coding RNA [NR_037871] 3.162 up 682
A_19_P00315584 LOC100130691 Homo sapiens uncharacterized LOC100130691 (LOC100130691), long non-coding RNA [NR_026966] 4.676 up 683
A_24_P400172 LOC100130691 Homo sapiens uncharacterized LOC100130691 (LOC100130691), long non-coding RNA [NR_026966] 4.813 up 684
A_19_P00315583 LOC100130691 Homo sapiens uncharacterized LOC100130691 (LOC100130691), long non-coding RNA [NR_026966] 4.019 up 685
A_23_P140876 ABCA3 Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 3 (ABCA3), mRNA [NM_001089] 4.707 up 686
A_23_P251680 COMT Homo sapiens catechol-O-methyltransferase (COMT), transcript variant 1, mRNA [NM_000754] 3.208 up 687
A_33_P3398897 QDPR Homo sapiens quinoid dihydropteridine reductase (QDPR), mRNA [NM_000320] 3.707 up 688
A_33_P3379091 SYNGR1 Homo sapiens synaptogyrin 1 (SYNGR1), transcript variant 1b, mRNA [NM_145731] 3.315 up 689
A_32_P114284 IKZF2 Homo sapiens IKAROS family zinc finger 2 (Helios) (IKZF2), transcript variant 2, mRNA [NM_001079526] 4.210 up 690
A_21_P0000089 ZFYVE28
















Homo sapiens ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) 
(RAC2), mRNA [NM_002872]
4.093 up 695
A_23_P78108 ALDOC Homo sapiens aldolase C, fructose-bisphosphate (ALDOC), mRNA [NM_005165] 3.162 up 696
A_24_P852756 HLA-DQA2 Homo sapiens major histocompatibility complex, class II, DQ alpha 2 (HLA-DQA2), mRNA [NM_020056] 3.768 up 697
A_21_P0002674 FLJ42351 Homo sapiens uncharacterized LOC400999 (FLJ42351), long non-coding RNA [NR_033871] 3.236 up 698
A_23_P887 IKBKE
Homo sapiens inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (IKBKE), 
transcript variant 1, mRNA [NM_014002]
3.164 up 699
A_23_P42144 PEX6 Homo sapiens peroxisomal biogenesis factor 6 (PEX6), mRNA [NM_000287] 4.714 up 700
A_21_P0000047 DISC1 Homo sapiens disrupted in schizophrenia 1 (DISC1), transcript variant g, mRNA [NM_001164544] 4.182 up 701
A_23_P40821 HPS3 Homo sapiens Hermansky-Pudlak syndrome 3 (HPS3), mRNA [NM_032383] 3.106 up 702
A_23_P83028 RECK Homo sapiens reversion-inducing-cysteine-rich protein with kazal motifs (RECK), mRNA [NM_021111] 3.700 up 703
A_33_P3741059 na Homo sapiens mRNA; cDNA DKFZp667K053 (from clone DKFZp667K053). [AL832882] 4.667 up 704
A_21_P0007122 ZBED5-AS1 Homo sapiens ZBED5 antisense RNA 1 (ZBED5-AS1), long non-coding RNA [NR_034137] 6.525 up 705
A_33_P3415216 MPV17 Homo sapiens MpV17 mitochondrial inner membrane protein (MPV17), mRNA [NM_002437] 3.625 up 706
A_21_P0014888 na
BC009371 adipocyte-specific adhesion molecule {Homo sapiens} (exp=-1; wgp=0; cg=0), partial (13%) 
[THC2642479]
3.289 up 707
A_24_P182539 ATG4C Homo sapiens autophagy related 4C, cysteine peptidase (ATG4C), transcript variant 1, mRNA [NM_032852] 3.153 up 708
A_21_P0002185 lnc-EFR3B-3 LNCipedia lincRNA (lnc-EFR3B-3), lincRNA [lnc-EFR3B-3:7] 3.121 up 709
A_23_P406350 MFSD3




Homo sapiens chromosome 10 open reading frame 128 (C10orf128), transcript variant 5, mRNA 
[NM_001288743]
3.766 up 711
A_23_P216655 TRIM14 Homo sapiens tripartite motif containing 14 (TRIM14), transcript variant 1, mRNA [NM_014788] 3.197 up 712
A_24_P55250 HDDC2 Homo sapiens HD domain containing 2 (HDDC2), mRNA [NM_016063] 3.197 up 713
A_23_P137848 MRPL24 Homo sapiens mitochondrial ribosomal protein L24 (MRPL24), transcript variant 1, mRNA [NM_145729] 4.168 up 714
A_23_P6535 KLHDC7B Homo sapiens kelch domain containing 7B (KLHDC7B), mRNA [NM_138433] 3.343 up 715
A_23_P131653 PIGF
Homo sapiens phosphatidylinositol glycan anchor biosynthesis, class F (PIGF), transcript variant 1, mRNA 
[NM_002643]
3.805 up 716
A_24_P49383 AAMDC Homo sapiens adipogenesis associated, Mth938 domain containing (AAMDC), mRNA [NM_024684] 4.607 up 717
A_24_P341019 TMEM230 Homo sapiens transmembrane protein 230 (TMEM230), transcript variant 2, mRNA [NM_001009924] 3.981 up 718
A_23_P17490 TMEM230 Homo sapiens transmembrane protein 230 (TMEM230), transcript variant 2, mRNA [NM_001009924] 3.575 up 719
A_23_P359904 PDDC1 Homo sapiens Parkinson disease 7 domain containing 1 (PDDC1), mRNA [NM_182612] 4.370 up 720
A_24_P245246 PIP4K2B Homo sapiens phosphatidylinositol-5-phosphate 4-kinase, type II, beta (PIP4K2B), mRNA [NM_003559] 3.808 up 721
A_23_P146209 RNF170 Homo sapiens ring finger protein 170 (RNF170), transcript variant 2, mRNA [NM_030954] 4.263 up 722
A_32_P129968 ZNF284 zinc finger protein 284 [Source:HGNC Symbol;Acc:HGNC:13078] [ENST00000421176] 4.609 up 723
A_33_P3361417 C6orf57 Homo sapiens chromosome 6 open reading frame 57 (C6orf57), mRNA [NM_145267] 3.328 up 724
A_33_P3271755 SIRT5 Homo sapiens sirtuin 5 (SIRT5), transcript variant 2, mRNA [NM_031244] 3.199 up 725
A_24_P40594 HOMEZ Homo sapiens homeobox and leucine zipper encoding (HOMEZ), mRNA [NM_020834] 3.636 up 726
A_23_P88753 TSR3 Homo sapiens TSR3, 20S rRNA accumulation, homolog (S. cerevisiae) (TSR3), mRNA [NM_001001410] 3.182 up 727
A_33_P3246007 APOA1BP Homo sapiens apolipoprotein A-I binding protein (APOA1BP), mRNA [NM_144772] 3.583 up 728
A_23_P61960 ATP6V0E2




Homo sapiens single-strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1), transcript variant 
1, mRNA [NM_014311]
3.739 up 730
A_23_P34307 PIGK Homo sapiens phosphatidylinositol glycan anchor biosynthesis, class K (PIGK), mRNA [NM_005482] 4.905 up 731
A_23_P201035 GBA Homo sapiens glucosidase, beta, acid (GBA), transcript variant 2, mRNA [NM_001005741] 3.233 up 732
A_23_P123454 NUDT18
Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 18 (NUDT18), mRNA 
[NM_024815]
3.472 up 733
A_24_P370670 ZMYM6NB Homo sapiens ZMYM6 neighbor (ZMYM6NB), mRNA [NM_001195156] 3.161 up 734
A_23_P431569 LOC100049716 Homo sapiens uncharacterized LOC100049716 (LOC100049716), long non-coding RNA [NR_122124] 3.237 up 735
A_33_P3261610 POLR3GL




Homo sapiens polymerase (RNA) III (DNA directed) polypeptide G (32kD)-like (POLR3GL), mRNA 
[NM_032305]
3.363 up 737
A_23_P56759 KRCC1 Homo sapiens lysine-rich coiled-coil 1 (KRCC1), mRNA [NM_016618] 5.416 up 738
A_23_P350574 FCRLB Homo sapiens Fc receptor-like B (FCRLB), transcript variant 1, mRNA [NM_001002901] 3.831 up 739
A_33_P3244117 STARD9
StAR-related lipid transfer (START) domain containing 9 [Source:HGNC Symbol;Acc:HGNC:19162] 
[ENST00000568493]
5.388 up 740
A_21_P0011317 XLOC_l2_004640 BROAD Institute lincRNA (XLOC_l2_004640), lincRNA [TCONS_l2_00008603] 4.070 up 741
A_33_P3329898 STARD9
StAR-related lipid transfer (START) domain containing 9 [Source:HGNC Symbol;Acc:HGNC:19162] 
[ENST00000564158]
6.349 up 742
A_23_P38677 SLMO1 Homo sapiens slowmo homolog 1 (Drosophila) (SLMO1), transcript variant 2, mRNA [NM_006553] 4.329 up 743
A_21_P0011320 XLOC_l2_004640 BROAD Institute lincRNA (XLOC_l2_004640), lincRNA [TCONS_l2_00008608] 4.518 up 744
A_23_P348298 SAC3D1 Homo sapiens SAC3 domain containing 1 (SAC3D1), mRNA [NM_013299] 3.423 up 745
A_23_P421401 PDGFRB Homo sapiens platelet-derived growth factor receptor, beta polypeptide (PDGFRB), mRNA [NM_002609] 3.382 up 746
A_24_P225616 RRM2 Homo sapiens ribonucleotide reductase M2 (RRM2), transcript variant 2, mRNA [NM_001034] 3.467 up 747
A_23_P408955 E2F2 Homo sapiens E2F transcription factor 2 (E2F2), mRNA [NM_004091] 3.640 up 748
A_23_P379614 OIP5 Homo sapiens Opa interacting protein 5 (OIP5), mRNA [NM_007280] 6.188 up 749
A_23_P115482 UBE2T Homo sapiens ubiquitin-conjugating enzyme E2T (UBE2T), mRNA [NM_014176] 3.469 up 750
A_33_P3313796 CCDC34 Homo sapiens coiled-coil domain containing 34 (CCDC34), transcript variant 1, mRNA [NM_030771] 6.087 up 751
A_32_P221256 MGC70870 Homo sapiens C-terminal binding protein 2 pseudogene (MGC70870), non-coding RNA [NR_003682] 3.296 up 752
A_33_P3330099 ARSD Homo sapiens arylsulfatase D (ARSD), mRNA [NM_001669] 3.511 up 753
A_33_P3357322 SMC2
Homo sapiens structural maintenance of chromosomes 2 (SMC2), transcript variant 1, mRNA 
[NM_001042550]
3.318 up 754
A_23_P48585 SALL2 Homo sapiens spalt-like transcription factor 2 (SALL2), transcript variant 1, mRNA [NM_005407] 4.469 up 755
A_23_P11862 C1orf112 Homo sapiens chromosome 1 open reading frame 112 (C1orf112), mRNA [NM_018186] 3.825 up 756
A_33_P3369153 KIF3C Homo sapiens kinesin family member 3C (KIF3C), mRNA [NM_002254] 4.126 up 757
A_21_P0007523 DDX11-AS1 Homo sapiens DDX11 antisense RNA 1 (DDX11-AS1), long non-coding RNA [NR_038927] 5.120 up 758
A_21_P0001702 lnc-CHD1L-1 LNCipedia lincRNA (lnc-CHD1L-1), lincRNA [lnc-CHD1L-1:3] 3.602 up 759
A_24_P106112 PKD2 Homo sapiens polycystic kidney disease 2 (autosomal dominant) (PKD2), mRNA [NM_000297] 4.008 up 760
A_32_P150891 DIAPH3 Homo sapiens diaphanous-related formin 3 (DIAPH3), transcript variant 1, mRNA [NM_001042517] 4.090 up 761
A_23_P251421 CDCA7 Homo sapiens cell division cycle associated 7 (CDCA7), transcript variant 1, mRNA [NM_031942] 7.153 up 762
A_23_P48088 CD27 Homo sapiens CD27 molecule (CD27), mRNA [NM_001242] 3.293 up 763
A_33_P3234202 DNASE1L3 Homo sapiens deoxyribonuclease I-like 3 (DNASE1L3), transcript variant 1, mRNA [NM_004944] 6.763 up 764
A_23_P120227 LBH Homo sapiens limb bud and heart development (LBH), mRNA [NM_030915] 3.176 up 765
A_23_P29594 RPL39L Homo sapiens ribosomal protein L39-like (RPL39L), mRNA [NM_052969] 5.154 up 766
A_24_P379820 ITM2C Homo sapiens integral membrane protein 2C (ITM2C), transcript variant 1, mRNA [NM_030926] 4.789 up 767
A_24_P402690 ITM2C Homo sapiens integral membrane protein 2C (ITM2C), transcript variant 1, mRNA [NM_030926] 5.317 up 768
A_23_P63789 ZWINT Homo sapiens ZW10 interacting kinetochore protein (ZWINT), transcript variant 2, mRNA [NM_032997] 5.233 up 769
A_33_P3212994 ZWINT Homo sapiens ZW10 interacting kinetochore protein (ZWINT), transcript variant 2, mRNA [NM_032997] 4.314 up 770
A_23_P26557 C16orf59 Homo sapiens chromosome 16 open reading frame 59 (C16orf59), mRNA [NM_025108] 4.543 up 771
A_33_P3317523 STMN1 Homo sapiens stathmin 1 (STMN1), transcript variant 1, mRNA [NM_203401] 3.754 up 772
A_33_P3423949 CBX2 Homo sapiens chromobox homolog 2 (CBX2), transcript variant 1, mRNA [NM_005189] 5.229 up 773
A_33_P3219256 BMPR1A Homo sapiens bone morphogenetic protein receptor, type IA (BMPR1A), mRNA [NM_004329] 6.520 up 774
A_19_P00805548 BMPR1A Homo sapiens bone morphogenetic protein receptor, type IA (BMPR1A), mRNA [NM_004329] 6.758 up 775
A_33_P3219475 MSANTD3-TMEFF1 Homo sapiens MSANTD3-TMEFF1 readthrough (MSANTD3-TMEFF1), mRNA [NM_001198812] 3.197 up 776
A_21_P0014379 ZNF793-AS1 Homo sapiens ZNF793 antisense RNA 1 (head to head) (ZNF793-AS1), long non-coding RNA [NR_110723] 3.108 up 777
A_19_P00808794 XLOC_l2_008221 BROAD Institute lincRNA (XLOC_l2_008221), lincRNA [TCONS_l2_00014842] 5.311 up 778
A_33_P3391476 CRYZ Homo sapiens crystallin, zeta (quinone reductase) (CRYZ), transcript variant 1, mRNA [NM_001130042] 3.921 up 779
A_23_P39067 SPIB
Homo sapiens Spi-B transcription factor (Spi-1/PU.1 related) (SPIB), transcript variant 1, mRNA 
[NM_003121]
3.114 up 780
A_23_P104046 BPNT1 Homo sapiens 3'(2'), 5'-bisphosphate nucleotidase 1 (BPNT1), transcript variant 1, mRNA [NM_006085] 3.319 up 781
A_21_P0012929 XLOC_l2_012319 BROAD Institute lincRNA (XLOC_l2_012319), lincRNA [TCONS_l2_00023251] 3.598 up 782
A_23_P120860 NIPSNAP1 Homo sapiens nipsnap homolog 1 (C. elegans) (NIPSNAP1), transcript variant 1, mRNA [NM_003634] 3.825 up 783
A_23_P88904 NTHL1 Homo sapiens nth endonuclease III-like 1 (E. coli) (NTHL1), mRNA [NM_002528] 5.161 up 784
A_23_P59528 ACN9 Homo sapiens ACN9 homolog (S. cerevisiae) (ACN9), mRNA [NM_020186] 4.086 up 785
A_24_P148811 RUVBL1 Homo sapiens RuvB-like AAA ATPase 1 (RUVBL1), mRNA [NM_003707] 4.711 up 786
A_23_P164814 C19orf57 Homo sapiens chromosome 19 open reading frame 57 (C19orf57), mRNA [NM_024323] 3.163 up 787
A_23_P133770 CCDC167 Homo sapiens coiled-coil domain containing 167 (CCDC167), mRNA [NM_138493] 5.743 up 788
A_33_P3260100 CCDC167 Homo sapiens coiled-coil domain containing 167 (CCDC167), mRNA [NM_138493] 3.682 up 789
A_23_P31116 ACOT13 Homo sapiens acyl-CoA thioesterase 13 (ACOT13), transcript variant 1, mRNA [NM_018473] 3.399 up 790
A_21_P0014321 ATP2A1-AS1
Homo sapiens ATP2A1 antisense RNA 1 (ATP2A1-AS1), transcript variant 1, long non-coding RNA 
[NR_046287]
3.342 up 791
A_24_P343095 DHFR Homo sapiens dihydrofolate reductase (DHFR), transcript variant 1, mRNA [NM_000791] 3.516 up 792
A_23_P32135 C9orf9 Homo sapiens chromosome 9 open reading frame 9 (C9orf9), mRNA [NM_018956] 4.538 up 793
A_33_P3764802 SIRT5 Homo sapiens sirtuin 5 (SIRT5), transcript variant 1, mRNA [NM_012241] 3.200 up 794
A_33_P3390778 TRIM46 Homo sapiens tripartite motif containing 46 (TRIM46), transcript variant 2, mRNA [NM_001256599] 7.981 up 795
A_23_P18413 TIMMDC1
Homo sapiens translocase of inner mitochondrial membrane domain containing 1 (TIMMDC1), mRNA 
[NM_016589]
3.460 up 796
A_23_P150009 ZDHHC16 Homo sapiens zinc finger, DHHC-type containing 16 (ZDHHC16), transcript variant 5, mRNA [NM_198046] 4.643 up 797
A_33_P3340025 GINS1 Homo sapiens GINS complex subunit 1 (Psf1 homolog) (GINS1), mRNA [NM_021067] 8.166 up 798
A_32_P1701 POLA1 Homo sapiens polymerase (DNA directed), alpha 1, catalytic subunit (POLA1), mRNA [NM_016937] 3.791 up 799
A_33_P3296372 EIF2B3
Homo sapiens eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa (EIF2B3), transcript 
variant 1, mRNA [NM_020365]
5.697 up 800
A_24_P73943 COX11




Homo sapiens processing of precursor 5, ribonuclease P/MRP subunit (S. cerevisiae) (POP5), transcript 
variant 1, mRNA [NM_015918]
4.298 up 802
A_23_P153098 HDHD2 Homo sapiens haloacid dehalogenase-like hydrolase domain containing 2 (HDHD2), mRNA [NM_032124] 8.984 up 803
A_23_P207517 PDK2 Homo sapiens pyruvate dehydrogenase kinase, isozyme 2 (PDK2), transcript variant 1, mRNA [NM_002611] 4.115 up 804
A_23_P90732 PNKD Homo sapiens paroxysmal nonkinesigenic dyskinesia (PNKD), transcript variant 3, mRNA [NM_001077399] 6.650 up 805
A_21_P0000034 COX11
Homo sapiens COX11 cytochrome c oxidase copper chaperone (COX11), transcript variant 1, mRNA 
[NM_004375]
9.076 up 806
A_23_P111000 PSMB9 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 9 (PSMB9), mRNA [NM_002800] 4.735 up 807
A_21_P0013869 FIRRE Homo sapiens firre intergenic repeating RNA element (FIRRE), long non-coding RNA [NR_026975] 4.800 up 808
A_21_P0013831 XLOC_l2_015821 BROAD Institute lincRNA (XLOC_l2_015821), lincRNA [TCONS_l2_00030598] 6.382 up 809
A_21_P0013832 FIRRE Homo sapiens firre intergenic repeating RNA element (FIRRE), long non-coding RNA [NR_026975] 6.660 up 810
A_21_P0011391 CHEK2 Homo sapiens checkpoint kinase 2 (CHEK2), transcript variant 3, mRNA [NM_001005735] 4.916 up 811
A_21_P0011475 CHEK2 Homo sapiens checkpoint kinase 2 (CHEK2), transcript variant 3, mRNA [NM_001005735] 4.347 up 812
A_21_P0011474 CHEK2 Homo sapiens checkpoint kinase 2 (CHEK2), transcript variant 3, mRNA [NM_001005735] 5.076 up 813
A_23_P203115 TMEM25 Homo sapiens transmembrane protein 25 (TMEM25), transcript variant 1, mRNA [NM_032780] 3.792 up 814
A_33_P3400152 ENTPD1-AS1 Homo sapiens ENTPD1 antisense RNA 1 (ENTPD1-AS1), long non-coding RNA [NR_038444] 3.372 up 815
A_23_P207400 BRCA1 Homo sapiens breast cancer 1, early onset (BRCA1), transcript variant 2, mRNA [NM_007300] 7.853 up 816
A_33_P3301524 XRCC3
Homo sapiens X-ray repair complementing defective repair in Chinese hamster cells 3 (XRCC3), transcript 
variant 1, mRNA [NM_001100119]
3.731 up 817
A_23_P53276 TIMELESS Homo sapiens timeless circadian clock (TIMELESS), mRNA [NM_003920] 3.801 up 818
A_23_P207201 CD79B
Homo sapiens CD79b molecule, immunoglobulin-associated beta (CD79B), transcript variant 3, mRNA 
[NM_001039933]
9.246 up 819
A_33_P3383970 TLR10 Homo sapiens toll-like receptor 10 (TLR10), transcript variant 1, mRNA [NM_030956] 5.577 up 820
A_33_P3264846 SAMD9L sterile alpha motif domain containing 9-like [Source:HGNC Symbol;Acc:HGNC:1349] [ENST00000610760] 7.353 up 821
A_23_P145874 SAMD9L sterile alpha motif domain containing 9-like [Source:HGNC Symbol;Acc:HGNC:1349] [ENST00000411955] 6.081 up 822
A_23_P42080 TMEM14A Homo sapiens transmembrane protein 14A (TMEM14A), mRNA [NM_014051] 4.647 up 823
A_24_P277155 HLTF Homo sapiens helicase-like transcription factor (HLTF), transcript variant 1, mRNA [NM_003071] 3.575 up 824
A_23_P88222 PLD4 Homo sapiens phospholipase D family, member 4 (PLD4), mRNA [NM_138790] 8.007 up 825
A_23_P342131 CYB561A3 Homo sapiens cytochrome b561 family, member A3 (CYB561A3), transcript variant 2, mRNA [NM_153611] 3.550 up 826
A_23_P16078 PAFAH1B3
Homo sapiens platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 (29kDa) (PAFAH1B3), 
transcript variant 2, mRNA [NM_002573]
3.412 up 827
A_33_P3372451 DNPH1
Homo sapiens 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 (DNPH1), transcript variant 2, mRNA 
[NM_199184]
4.573 up 828
A_33_P3258712 LOC101928000 PREDICTED: Homo sapiens uncharacterized LOC101928000 (LOC101928000), ncRNA [XR_243583] 3.267 up 829
A_33_P3304824 LINC00618




Homo sapiens SRP14 antisense RNA1 (head to head) (SRP14-AS1), transcript variant 1, long non-coding 
RNA [NR_040059]
8.796 up 831
A_23_P66311 DNASE1 Homo sapiens deoxyribonuclease I (DNASE1), mRNA [NM_005223] 3.954 up 832
A_24_P296907 THAP8 Homo sapiens THAP domain containing 8 (THAP8), mRNA [NM_152658] 5.831 up 833
A_24_P925314 GM2A Homo sapiens GM2 ganglioside activator (GM2A), transcript variant 1, mRNA [NM_000405] 3.427 up 834
A_23_P129064 GATM
Homo sapiens glycine amidinotransferase (L-arginine:glycine amidinotransferase) (GATM), mRNA 
[NM_001482]
3.217 up 835
A_24_P417352 LOC102725284 immunoglobulin heavy constant mu [Source:HGNC Symbol;Acc:HGNC:5541] [ENST00000610838] 3.287 up 836
A_33_P3263317 na
Homo sapiens cDNA FLJ46564 fis, clone THYMU3040746, highly similar to Ig gamma-2 chain C region. 
[AK128421]
3.711 up 837
A_24_P276576 FCRLA Homo sapiens Fc receptor-like A (FCRLA), transcript variant 2, mRNA [NM_032738] 15.711 up 838
A_23_P46039 FCRLA Homo sapiens Fc receptor-like A (FCRLA), transcript variant 2, mRNA [NM_032738] 14.672 up 839
A_23_P217901 TSTD1
Homo sapiens thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 (TSTD1), transcript 
variant 1, mRNA [NM_001113207]
4.731 up 840
A_23_P30736 HLA-DOB Homo sapiens major histocompatibility complex, class II, DO beta (HLA-DOB), mRNA [NM_002120] 4.305 up 841
A_33_P3397910 lnc-RAB1A-1 ALU1_HUMAN (P39188) Alu subfamily J sequence contamination warning entry, partial (5%) [THC2680929] 3.461 up 842
A_23_P49988 KRTAP4-2 Homo sapiens keratin associated protein 4-2 (KRTAP4-2), mRNA [NM_033062] 3.223 up 843
A_21_P0002860 na 0 3.501 up 844
A_33_P3565787 PSMG3-AS1




Homo sapiens melanoma associated antigen (mutated) 1 (MUM1), transcript variant 1, mRNA 
[NM_032853]
4.407 up 846
A_23_P86731 ZNF239 Homo sapiens zinc finger protein 239 (ZNF239), transcript variant 1, mRNA [NM_005674] 7.140 up 847
A_32_P24140 GAS2 Homo sapiens growth arrest-specific 2 (GAS2), transcript variant 1, mRNA [NM_005256] 5.144 up 848
A_33_P3371341 FAM66C Homo sapiens family with sequence similarity 66, member C (FAM66C), long non-coding RNA [NR_026788] 4.237 up 849
A_33_P3238295 FAM66C Homo sapiens family with sequence similarity 66, member C (FAM66C), long non-coding RNA [NR_026788] 3.833 up 850
A_21_P0000742 MYLK-AS1 Homo sapiens MYLK antisense RNA 1 (MYLK-AS1), transcript variant 1, long non-coding RNA [NR_038266] 5.233 up 851
A_33_P3271395 LOC100129534








Homo sapiens chromosome 11 open reading frame 49 (C11orf49), transcript variant 1, mRNA 
[NM_001003676]
3.538 up 854
A_33_P3252369 TMEM182 Homo sapiens transmembrane protein 182 (TMEM182), mRNA [NM_144632] 7.132 up 855
A_24_P268729 HEMK1 Homo sapiens HemK methyltransferase family member 1 (HEMK1), mRNA [NM_016173] 6.326 up 856
A_23_P256835 TRAPPC12 Homo sapiens trafficking protein particle complex 12 (TRAPPC12), mRNA [NM_016030] 3.259 up 857
A_23_P420256 C2orf43 Homo sapiens chromosome 2 open reading frame 43 (C2orf43), transcript variant 1, mRNA [NM_021925] 8.585 up 858
A_24_P914513 BCKDHB
Homo sapiens branched chain keto acid dehydrogenase E1, beta polypeptide (BCKDHB), transcript variant 
1, mRNA [NM_183050]
4.744 up 859
A_33_P3389298 ZNF30 Homo sapiens zinc finger protein 30 (ZNF30), transcript variant 1, mRNA [NM_001099438] 5.286 up 860
A_32_P151782 na AGENCOURT_14064404 NIH_MGC_172 Homo sapiens cDNA 5', mRNA sequence [CD248433] 6.827 up 861
A_23_P39517 SRBD1 Homo sapiens S1 RNA binding domain 1 (SRBD1), mRNA [NM_018079] 3.404 up 862
A_24_P626931 UBE3D ubiquitin protein ligase E3D [Source:HGNC Symbol;Acc:HGNC:21381] [ENST00000503942] 4.684 up 863
A_21_P0011592 LINC00910
Homo sapiens long intergenic non-protein coding RNA 910 (LINC00910), transcript variant 2, long non-
coding RNA [NR_027412]
4.756 up 864
A_21_P0012925 XLOC_l2_012210 BROAD Institute lincRNA (XLOC_l2_012210), lincRNA [TCONS_l2_00023087] 3.984 up 865
A_24_P299355 GRAPL Homo sapiens GRB2-related adaptor protein-like (GRAPL), mRNA [NM_001129778] 6.365 up 866
A_23_P23719 VPS45




Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A), mRNA 
[NM_006305]
3.143 up 868
A_33_P3275510 C20orf196 chromosome 20 open reading frame 196 [Source:HGNC Symbol;Acc:HGNC:26318] [ENST00000303142] 3.460 up 869
A_21_P0007119 FLJ37035 Homo sapiens uncharacterized LOC399821 (FLJ37035), long non-coding RNA [NR_033847] 3.456 up 870
A_23_P86100 KLHDC9 Homo sapiens kelch domain containing 9 (KLHDC9), transcript variant 2, mRNA [NM_001007255] 4.806 up 871
A_33_P3304963 LRRC27 Homo sapiens leucine rich repeat containing 27 (LRRC27), transcript variant 4, mRNA [NM_001143759] 4.508 up 872
A_23_P123086 PSMG3-AS1








Homo sapiens cysteine conjugate-beta lyase, cytoplasmic (CCBL1), transcript variant 1, mRNA 
[NM_004059]
6.120 up 875
A_24_P398323 TRIM34 Homo sapiens tripartite motif containing 34 (TRIM34), transcript variant 4, mRNA [NM_001003827] 3.971 up 876
A_24_P573533 CBWD5 Homo sapiens COBW domain containing 5 (CBWD5), transcript variant 1, mRNA [NM_001024916] 3.310 up 877
A_24_P100830 AMN1
Homo sapiens antagonist of mitotic exit network 1 homolog (S. cerevisiae) (AMN1), transcript variant 3, 
mRNA [NM_001278412]
3.439 up 878
A_21_P0014380 na PREDICTED: Homo sapiens uncharacterized LOC100507486 (LOC100507486), misc_RNA [XR_109525] 3.584 up 879
A_33_P3405743 CRYZ Homo sapiens crystallin, zeta (quinone reductase) (CRYZ), transcript variant 1, mRNA [NM_001130042] 3.885 up 880
A_33_P3233273 LRRC61 Homo sapiens leucine rich repeat containing 61 (LRRC61), transcript variant 1, mRNA [NM_001142928] 3.951 up 881
A_23_P320717 COG4 Homo sapiens component of oligomeric golgi complex 4 (COG4), transcript variant 1, mRNA [NM_015386] 3.166 up 882
A_33_P3277514 BTK




Homo sapiens Bruton agammaglobulinemia tyrosine kinase (BTK), transcript variant 1, mRNA 
[NM_000061]
3.916 up 884
A_33_P3531828 LARS Homo sapiens leucyl-tRNA synthetase (LARS), mRNA [NM_020117] 3.856 up 885
A_33_P3217834 SMARCAL1
Homo sapiens SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a-
like 1 (SMARCAL1), transcript variant 1, mRNA [NM_014140]
4.416 up 886
A_23_P96761 ACADM
Homo sapiens acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM), transcript variant 1, mRNA 
[NM_000016]
6.941 up 887
A_23_P332042 RECQL5 Homo sapiens RecQ protein-like 5 (RECQL5), transcript variant 1, mRNA [NM_004259] 3.990 up 888
A_33_P3210521 C2orf43 Homo sapiens chromosome 2 open reading frame 43 (C2orf43), transcript variant 1, mRNA [NM_021925] 6.877 up 889
A_23_P118406 C17orf62




Homo sapiens primase and polymerase (DNA-directed) (PRIMPOL), transcript variant 1, mRNA 
[NM_152683]
3.368 up 891
A_23_P90333 ZNF404 Homo sapiens zinc finger protein 404 (ZNF404), mRNA [NM_001033719] 7.140 up 892
A_23_P84922 HDAC8 Homo sapiens histone deacetylase 8 (HDAC8), transcript variant 1, mRNA [NM_018486] 3.149 up 893
A_33_P3235987 PIN4
Homo sapiens protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) (PIN4), transcript 
variant 1, mRNA [NM_006223]
3.296 up 894
A_24_P207139 PML Homo sapiens promyelocytic leukemia (PML), transcript variant 1, mRNA [NM_033238] 3.845 up 895
A_23_P300076 IQCG Homo sapiens IQ motif containing G (IQCG), transcript variant 1, mRNA [NM_032263] 3.837 up 896
A_23_P215070 CEP41 Homo sapiens centrosomal protein 41kDa (CEP41), transcript variant 1, mRNA [NM_018718] 5.563 up 897
A_23_P23102 ZSCAN20 Homo sapiens zinc finger and SCAN domain containing 20 (ZSCAN20), mRNA [NM_145238] 3.825 up 898
A_23_P92954 HSD17B4
Homo sapiens hydroxysteroid (17-beta) dehydrogenase 4 (HSD17B4), transcript variant 2, mRNA 
[NM_000414]
3.112 up 899
A_23_P353717 RMI2 Homo sapiens RecQ mediated genome instability 2 (RMI2), mRNA [NM_152308] 4.385 up 900
A_32_P96692 POLH Homo sapiens polymerase (DNA directed), eta (POLH), transcript variant 1, mRNA [NM_006502] 3.993 up 901
A_33_P3313830 LINC01184








Homo sapiens RNASEH1 antisense RNA 1 (RNASEH1-AS1), transcript variant 3, long non-coding RNA 
[NR_038431]
3.252 up 904
A_24_P162287 CEP250 Homo sapiens centrosomal protein 250kDa (CEP250), mRNA [NM_007186] 3.166 up 905
A_23_P129014 EFCAB11 Homo sapiens EF-hand calcium binding domain 11 (EFCAB11), transcript variant 1, mRNA [NM_145231] 5.168 up 906
A_21_P0010470 lnc-MAPK8IP2-1 LNCipedia lincRNA (lnc-MAPK8IP2-1), lincRNA [lnc-MAPK8IP2-1:12] 3.256 up 907
A_21_P0014568 LOC100507616
PREDICTED: Homo sapiens uncharacterized LOC100507616 (LOC100507616), transcript variant X1, ncRNA 
[XR_110328]
3.421 up 908
A_33_P3407895 RINL Homo sapiens Ras and Rab interactor-like (RINL), transcript variant 1, mRNA [NM_001195833] 3.469 up 909
A_23_P357104 ANXA6 Homo sapiens annexin A6 (ANXA6), transcript variant 1, mRNA [NM_001155] 4.033 up 910
A_23_P163143 ACYP1
Homo sapiens acylphosphatase 1, erythrocyte (common) type (ACYP1), transcript variant 4, mRNA 
[NM_001302617]
5.273 up 911
A_23_P334218 TBC1D31 Homo sapiens TBC1 domain family, member 31 (TBC1D31), transcript variant 1, mRNA [NM_145647] 3.718 up 912
A_24_P14260 CARD8




Homo sapiens methylcrotonoyl-CoA carboxylase 1 (alpha) (MCCC1), transcript variant 1, mRNA 
[NM_020166]
3.951 up 914
A_23_P155477 C3orf18 Homo sapiens chromosome 3 open reading frame 18 (C3orf18), transcript variant 1, mRNA [NM_016210] 4.289 up 915
A_23_P415021 METTL7A Homo sapiens methyltransferase like 7A (METTL7A), mRNA [NM_014033] 5.115 up 916
A_23_P200838 KMO Homo sapiens kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) (KMO), mRNA [NM_003679] 3.159 up 917
A_24_P77082 KMO Homo sapiens kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) (KMO), mRNA [NM_003679] 4.662 up 918
A_24_P175612 SFXN2 Homo sapiens sideroflexin 2 (SFXN2), mRNA [NM_178858] 3.242 up 919
A_33_P3401647 PPP1R14A
Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 14A (PPP1R14A), transcript variant 1, 
mRNA [NM_033256]
7.542 up 920
A_33_P3416712 LOC400958 Homo sapiens uncharacterized LOC400958 (LOC400958), long non-coding RNA [NR_036586] 5.611 up 921
A_23_P65983 CCDC102A Homo sapiens coiled-coil domain containing 102A (CCDC102A), mRNA [NM_033212] 3.513 up 922
Differentially expressed genes were assessed by Moderated T-Test (see Supplemental Methods).
Rank Function Name Number of genes/pathway P Impact Factor
1 Antigen processing and presentation 5 0.03739 82.185
2 Phosphatidylinositol signaling system 6 0.00813 22.084
3 Adherens junction 5 0.03085 18.065
4 B cell receptor signaling pathway 10 0.00000 15.474
5 Regulation of actin cytoskeleton 11 0.01035 6.809
6 Fc epsilon RI signaling pathway 6 0.00866 6.569
7 Melanoma 6 0.00625 6.442
8 Cell adhesion molecules (CAMs) 7 0.03665 5.913
9 Colorectal cancer 6 0.01379 5.827
10 Acute myeloid leukemia 5 0.00975 5.813
11 Pathways in cancer 14 0.02175 5.456
12 Glioma 5 0.01674 5.44
13 Prostate cancer 6 0.01790 5.344
Table S4. Pathway and GO categories differentially represented in BCRlow and BCRhigh MCL cells






Nominal P-Value FDR Q-Value
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_DN 57 -0.64277 -2.45527 0.00000 0.00000
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN 78 -0.57130 -2.32747 0.00000 0.00000
MOOTHA_VOXPHOS 84 -0.55872 -2.28949 0.00000 0.00028
BASSO_CD40_SIGNALING_DN 55 -0.58473 -2.25370 0.00000 0.00021




91 -0.52801 -2.18743 0.00000 0.00014
YU_MYC_TARGETS_DN 48 -0.58498 -2.17545 0.00000 0.00012
KANG_DOXORUBICIN_RESISTANCE_UP 49 -0.59507 -2.15912 0.00000 0.00031
PYEON_HPV_POSITIVE_TUMORS_UP 84 -0.51976 -2.13562 0.00000 0.00047
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 74 -0.53031 -2.12988 0.00000 0.00051
SANA_RESPONSE_TO_IFNG_UP 64 -0.54144 -2.10834 0.00000 0.00070
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 41 -0.57968 -2.09385 0.00000 0.00079
REACTOME_TELOMERE_MAINTENANCE 72 -0.51982 -2.08997 0.00000 0.00073
ISHIDA_E2F_TARGETS 47 -0.56699 -2.08842 0.00000 0.00067
CROONQUIST_IL6_DEPRIVATION_DN 90 -0.49985 -2.08417 0.00000 0.00069
REN_BOUND_BY_E2F 58 -0.52731 -2.05434 0.00000 0.00107
ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_DN 41 -0.55371 -2.00415 0.00000 0.00261
WAKASUGI_HAVE_ZNF143_BINDING_SITES 57 -0.52023 -2.00376 0.00159 0.00247
WIELAND_UP_BY_HBV_INFECTION 93 -0.48095 -2.00256 0.00000 0.00234
REACTOME_DNA_REPAIR 100 -0.48007 -1.98779 0.00000 0.00265
WOO_LIVER_CANCER_RECURRENCE_DN 55 -0.52017 -1.97602 0.00000 0.00297
KAUFFMANN_MELANOMA_RELAPSE_UP 57 -0.51877 -1.97578 0.00000 0.00283
REACTOME_G2_M_CHECKPOINTS 39 -0.55443 -1.97193 0.00000 0.00297
KEGG_PEROXISOME 61 -0.49775 -1.95369 0.00000 0.00373
KEGG_PYRIMIDINE_METABOLISM 86 -0.47361 -1.95241 0.00000 0.00369
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 67 -0.49561 -1.95205 0.00000 0.00354
ZHANG_TLX_TARGETS_UP 79 -0.48407 -1.94407 0.00000 0.00398
SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP 69 -0.48185 -1.92280 0.00000 0.00554
MORI_LARGE_PRE_BII_LYMPHOCYTE_DN 56 -0.50942 -1.91841 0.00000 0.00570
KEGG_TYPE_I_DIABETES_MELLITUS 36 -0.54784 -1.91498 0.00000 0.00560
BURTON_ADIPOGENESIS_3 89 -0.45991 -1.91036 0.00000 0.00572
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_UP 86 -0.45730 -1.90216 0.00161 0.00621
REACTOME_TRANSCRIPTION_COUPLED_NER_TC_NER 42 -0.52377 -1.90046 0.00000 0.00613
LEE_EARLY_T_LYMPHOCYTE_UP 81 -0.46723 -1.89848 0.00000 0.00615
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR 70 -0.47887 -1.89808 0.00000 0.00600
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_UP 100 -0.45255 -1.89449 0.00000 0.00614
SIG_BCR_SIGNALING_PATHWAY 46 -0.50867 -1.87878 0.00000 0.00725
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN 47 -0.51505 -1.87696 0.00000 0.00721
VERNELL_RETINOBLASTOMA_PATHWAY_UP 64 -0.48012 -1.87643 0.00164 0.00716
SONG_TARGETS_OF_IE86_CMV_PROTEIN 60 -0.48315 -1.87443 0.00000 0.00722
KEGG_NUCLEOTIDE_EXCISION_REPAIR 43 -0.51015 -1.87328 0.00164 0.00719
CROONQUIST_NRAS_SIGNALING_DN 66 -0.47718 -1.87134 0.00000 0.00724
RAMALHO_STEMNESS_DN 61 -0.48163 -1.87126 0.00000 0.00709
GRADE_METASTASIS_DN 42 -0.51037 -1.86763 0.00332 0.00730
PRAMOONJAGO_SOX4_TARGETS_DN 44 -0.51644 -1.86716 0.00000 0.00715
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN 39 -0.52469 -1.85699 0.00000 0.00789
WINTER_HYPOXIA_DN 45 -0.50350 -1.85265 0.00000 0.00812
KLEIN_TARGETS_OF_BCR_ABL1_FUSION 39 -0.51916 -1.84838 0.00000 0.00834
WU_APOPTOSIS_BY_CDKN1A_VIA_TP53 46 -0.50415 -1.84734 0.00000 0.00822
REACTOME_MEIOTIC_RECOMBINATION 72 -0.46258 -1.84729 0.00000 0.00806
REACTOME_DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT
_THE_CENTROMERE 57 -0.48821 -1.84263 0.00163 0.00842
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN 46 -0.51149 -1.84091 0.00000 0.00834
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 80 -0.45159 -1.83489 0.00000 0.00875
WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP 48 -0.49467 -1.82950 0.00000 0.00912
BROWNE_INTERFERON_RESPONSIVE_GENES 61 -0.46999 -1.82879 0.00000 0.00900
GRABARCZYK_BCL11B_TARGETS_DN 41 -0.51471 -1.82742 0.00169 0.00889
JAIN_NFKB_SIGNALING 72 -0.45657 -1.82466 0.00000 0.00911
MARTINEZ_RESPONSE_TO_TRABECTEDIN 45 -0.49161 -1.82280 0.00165 0.00915
KIM_GERMINAL_CENTER_T_HELPER_UP 54 -0.47593 -1.80912 0.00165 0.01068
REACTOME_NUCLEOTIDE_EXCISION_REPAIR 47 -0.48685 -1.79712 0.00168 0.01224
MORI_IMMATURE_B_LYMPHOCYTE_UP 50 -0.48321 -1.79501 0.00491 0.01236
HUTTMANN_B_CLL_POOR_SURVIVAL_DN 50 -0.47818 -1.76558 0.00000 0.01688
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 71 -0.44228 -1.76109 0.00159 0.01771
PID_FANCONI_PATHWAY 45 -0.48904 -1.75872 0.00325 0.01799
JIANG_AGING_HYPOTHALAMUS_UP 43 -0.49043 -1.75646 0.00165 0.01819
CHICAS_RB1_TARGETS_LOW_SERUM 85 -0.41979 -1.74780 0.00000 0.01964
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_DN 61 -0.44533 -1.74122 0.00320 0.02091
REACTOME_SYNTHESIS_OF_DNA 88 -0.42086 -1.73437 0.00157 0.02225
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION 42 -0.47820 -1.72246 0.00162 0.02495
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP 70 -0.43364 -1.71998 0.00000 0.02516
GAVIN_FOXP3_TARGETS_CLUSTER_P6 74 -0.43022 -1.71931 0.00324 0.02494
COATES_MACROPHAGE_M1_VS_M2_UP 64 -0.44386 -1.71656 0.00162 0.02543
KESHELAVA_MULTIPLE_DRUG_RESISTANCE 72 -0.42945 -1.71176 0.00318 0.02660
BURTON_ADIPOGENESIS_PEAK_AT_16HR 40 -0.48610 -1.68823 0.00498 0.03372
HOWLIN_PUBERTAL_MAMMARY_GLAND 46 -0.46024 -1.68665 0.00796 0.03382
REACTOME_TRNA_AMINOACYLATION 41 -0.46911 -1.67962 0.00659 0.03592
PID_BCR_5PATHWAY 64 -0.42934 -1.65977 0.00161 0.04395
OXFORD_RALA_OR_RALB_TARGETS_UP 46 -0.44430 -1.65210 0.00663 0.04706
ROSS_AML_WITH_MLL_FUSIONS 66 -0.41646 -1.64851 0.00000 0.04830
SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES 35 -0.48680 -1.64517 0.00336 0.04936
Table S5. Gene Set  upregulated in BCRhigh MCL cells respect to BCRlow MCL cells according to Gene Set Enrichment Analysis (GSEA)
Table S6. qRT-PCR details
Gene 
name





AKT3 GCTTGTACCTCCTTTTAAACCTC CATGCAGTCCATACCATCCTC TGAGACAGATACTAGATATTTTGATGAAGAATTTACAGCT 130 Hs.PT.58.38907880 0.998 3.308
B2M CCTGAATCTTTGGAGTACGCT GGCATTCCTGAAGCTGACA CTAAGGCCACGGAGCGAGACATC 118 B2M 0.997 3.280
BTK TGTATAGCAAGTTCAGCAGCAA ATCTCTCATATGGCATCTTCCC CCCACATCAAAACCCCAAAAGCCC 93 Hs.PT.56a.38768830 0.996 3.323
CD79b CAGCTGAGCCAGTACCAG TGTGCCAAGGTGCTGAATC 5'AGCCAGATCGGAGGACCGG 73 Hs.PT.58.40462637 0.996 3.390
PIK3CD TGCTCCAAAGACATCCAGTATC GGCTTCGTTAAACTTCACTCG TCTGTTTTCCCCAGTGCCAGGG 96 Hs.PT.58.39393086 0.984 3.377
SYK CTGGAGCTTTGGAGTGTTGA CGCTCTCCTTTCTCTAACATAGC TGCCCATAGGAGAATGCTTCCCAC 105 Hs.PT.5839642284 0.997 3.346
BCL2 AGCCAGGAGAAATCAAACAGAG GATGACTGAGTACCTGAACCG CAGGATAACGGAGGCTGGGATGC 117 Hs.PT.56a.2905156 0.996 3.301
Note: ID, assay name according to IDT producer; R2, correlation coefficient; Slope, slope of the standar curve.
